



M.A.G.I.C. MEDS RX™

MEDICATION ASSISTANCE GUIDE FOR IMPROVING CARE

GLOSSARY

HOW TO USE M.A.G.I.C.

ALPHABETICAL LIST OF ALL MEDICATIONS

A-E

F-J

K-O

P-T

U-Z

PROGRAM CAVEATS

&

FEDERAL POVERTY LIMIT CUTOFFS

PATIENT ASSISTANCE PROGRAMS BY MANUFACTURER

PROGRAMS & MEDICATIONS BY DISEASE STATE/CONDITION

ANTI-MIGRAINE

ANTITHROMBOTICS

AUTO-IMMUNE

CARDIOVASCULAR

DIABETES&INSULIN

INFECTIOUS DISEASE
(ACUTE&HIV)

INHALERS (RESPIRATORY)

NEUROLOGY&PSYCHIATRY

ONCOLOGY

ADDITIONAL RESOURCES (Welvista, RxOutreach, Walmart \$4.00 list, Care foundations)

RE-ENROLLMENT PROCESS PER PATIENT ASSISTANCE PROGRAM

REFILL REQUEST PROCESS

Purpose/Background

Medication adherence is largely impacted by patient specific barriers, one of the most crucial being financial constraints of affording their medications. There are resources from drug manufacturers and alternative programs to eliminate financial constraint of medication adherence. The resources available include:

1. **Patient assistance program (PAP)** - Drug manufacturers provide medications completely **free of charge** for low-income uninsured or Medicare patients, shipped directly to patients' home, primary care provider (PCP) office, or other designated address (i.e. infusion medications should be mailed to infusion center where patient has confirmed follow-up), depending on program eligibility. Covers almost **ALL** medications
 - a. Documentation required: program specific (none to needing income proof)
 - b. Process time: 2-7 days
2. **Welvista** – state run program, has limited formulary of medications
 - a. Documentation required: requires income documentation for all members of household,
 - b. Process time: 10-14 days
3. **RxOutreach** – nationwide program, has limited formulary for medications not covered by other PAP programs
 - a. Documentation required: None
 - b. Process time: 7-10 days
4. **Copay cards** – typically available to commercially insured patients or one-time uses in certain circumstances (outside the scope of this document)
5. **Walmart \$4.00 prescription list** – limited formulary of medications available at Walmart that may be more affordable via a prescription than at other pharmacies
6. **Care foundations** – foundations set up by donors for financially constrained patients for medications not covered by other programs (limited funds available)

This document encompasses comprehensive access to patient assistance programs (PAP) for almost all medications (see [additional resources](#) for medications not included). Patient eligibility is dependent upon:

- Income level based on the federal poverty limit (FPL), which varies yearly
 - Programs will either require proof of documentation or run electronic income verification (which will **NOT** affect a patient's credit score)
- Insurance status (must be uninsured or Medicare)

This **interactive document (clickable)** will allow for uninsured and low income patients to be enrolled in a patient assistance program and provide them with up to one year of medication **free-of-charge**. Following calendar year from enrollment date, subsequent application will need submitted for re-enrollment.

Barriers to utilizing [Welvista](#) through the state of South Carolina are:

- Cumbersome enrollment process, more than a patient can understand and above the appropriate level of health literacy
- 10-14 day processing time for applications
- Limited formulary
- Requirement of proof of income for all members within the household
 - Most patients do not have available during hospitalization
- FPL threshold of $\leq 250\%$ (stricter than most PAP)
 - Many patients can qualify for their individual medication with the higher threshold cutoffs for individual manufacturer PAP
- Medications also need e-scribed to Welvista or, if not originally e-scribed, will need mailed via the postal service to Welvista.

Patients are provided an expansive amount of information during their admission and at time of discharge. Many times, patients realize when they arrive at a pharmacy or arrive home, they may be uncertain of the appropriate steps to enroll in a PAP program, returning to a healthcare institution when their initial medication fill runs out. This interactive PAP tool enables our healthcare team to alleviate the financial burden and enrollment difficulties patients face alone outside of a healthcare institution.

Roles

Initial encounter

- a. Ensure appropriate insurance verification and upload into electronic health record

Case manager or office staff of designated area/clinic

- b. Determine patient eligibility based on manufacturer PAP
- c. Assist with completing patient contact information and income verification
- d. Assist patient with completing application
- e. Fax application for completion

How to use MAGIC (document is interactive, clickable)

1. Find desired medication via alphabetical directory or medications by disease state/condition
 - a. TIP: Use CTRL + F to quickly search for medication
2. You will be directed to the manufacturer program eligibility criteria for the selected medication
3. If patient meets criteria, click on the link of individual medication or on "Medications eligible for assistance" (depending on program) to be taken directly to PAP application
4. Complete application and fax to program (excludes Pfizer RxConnect-must apply online or call)

ALPHABETICAL LIST OF ALL MEDICATIONS

A-E

[Abilify Maintena \(Aripiprazole\) For Extended Release Injectable SUSPension](#)

[Abraxane® \(Paclitaxel Protein-Bound Particles For Injectable SUSPension \(Albumin-Bound\)\)](#)

[ACANYA® \(clindamycin phosphate and benzoyl peroxide\) Gel, 1.2% or 2.5%, for Topical](#)

[Actemra \(Tocilizumab\)](#)

[Activase \(Alteplase\)](#)

[Acuvail \(Ketorolac Tromethamine\) Ophthalmic Solution](#)

[Adacel® \(Tetanus Toxoid, Reduced Diphtheria Toxoid And Acellular Pertussis Vaccine Adsorbed\)](#)

[Adakveo® \(Crizanlizumab-Tmca\)](#)

[Adempas \(riociguat\)](#)

[Admelog® \(Insulin Lispro Injection\) 100 Units/mL](#)

[Advair \(Diskus Or HFA\) \(Fluticasone/Salmeterol\)](#)

[AeroChamber Plus Flow-Vu](#)

[Afinitor Disperz® \(Everolimus SUSPension\)](#)

[Afinitor® \(Everolimus\)](#)

[Aimovig \(Erenumab\)](#)

[Alcensa \(Alectinib\)](#)

[ALDARA Cream 5%](#)

[Aliqopa \(copanlisib\)](#)

[Alimta® \(Pemetrexed For Injection\)](#)

| |
|--|
| Alloderm |
| Alomide® (Lodoxamide Tromethamine Solution) |
| Alphagan P (Brimonidine Tartrate) Ophthalmic Solution |
| Amitiza (lubiprostone) |
| ANCOBON (flucytosine) capsules |
| ANGELIQ (drospirenone and estradiol) |
| Anoro Ellipta (Umeclidinium/Vilanterol) |
| Apidra® (Insulin Glulisine Injection) 100 Units/mL |
| APLENZIN (bupropion hydrobromide) Extended-Release Tablets |
| Aptom® (eslicarbazepine acetate) |
| Aptivus (Tipranavir) |
| Aranesp (Darbepoetin Alfa) |
| ARAZLO (tazarotene Lotion, 0.045%) |
| Arixtra (Fondaparinux) |
| Armour Thyroid (Thyroid Tablets, USP) Tablets |
| Arnuity Ellipta (Fluticasone) |
| Aromasin® (Exemestane) Tablets |
| Arthrotec® (Diclofenac Sodium/Misoprostol) Tablets |
| ATOPICLAIR Nonsteroidal Cream 100 g Tube |
| Atrovent HFA (Ipratropium) |
| Avastin (Bevacizumab) |
| Avsola (Infliximab-Axxq) |
| Avycaz (Avibactam/Ceftazidime) |
| Balversa (Erdafitinib) Tablets |
| Baqsimi® (Glucagon) Nasal Powder |
| Basaglar® (Insulin Glargine Injection) |
| Beconase AQ (Beclomethasone Dipropionate Nasal Spray) |
| Belsomra® (Suvorexant) C-IV |
| Bendeka (Bendamustine) |
| Benefix® Coagulation Factor IX (Recombinant) |
| Benlysta (Belimumab) |
| BENZAMYCIN GEL |
| Beovu® (Brolucizumab-Dbll) Injection |
| BESPONSA (inotuzumab) |
| BETASERON (interferon beta-1b) |
| Betoptic S® (Betaxolol Hydrochloride SUSPension) |
| Bevespi Aerosphere (Glycopyrrolate/Formoterol) |
| BIAFINE |
| BiDil (isosorbide dinitrate/hydralazine) |
| BILTRICIDE (praziquantel) |
| Blenrep (Belantamab) |
| Blincyto (Blinatumomab) |

| |
|---|
| Boostrix (Tdap Vaccine) |
| BOSULIF (bosutinib) |
| Botox (Onabotulinumtoxina) |
| BRAFTOVI (encoarfenib) |
| Breo Ellipta (Fluticasone/Vilanterol) |
| Breztri Aerosphere (Budesonide/Glycopyrrrolate/Formoterol) |
| Brilinta (Ticagrelor) |
| BRYHALI (halobetasol propionate) Lotion |
| Bydureon (Exenatide Extended Release) |
| Byetta (Exenatide) |
| Bystolic (Nebivolol) Tablets |
| Caduet (Amlodipine/Atorvastatin) |
| Calquence (Acalabrutinib) |
| CAMPTOSAR (irinotecan) |
| CAMZYOS (mavacamten) |
| Canasa (Mesalamine) Suppository |
| Cancidas® (Caspofungin Acetate) For Injection |
| CARAC (fluorouracil cream) |
| Carafate (Sucralfate) Oral SUSPension |
| Carbatrol (carbamazepine extended-release) capsules |
| Cathflo Activase (Alteplase) |
| Caverject® (Alprostadil) Injection |
| Caverject® Impulse® (Alprostadil) Injection |
| Celebrex® (Celecoxib) Capsules |
| Celontin® (Methsuximide) Capsules, USP |
| Chantix® (Varenicline) Tablets |
| Cialis® (Tadalafil) Tablets |
| Cibinqo™ (Abrocitinib) Tablets |
| Cimduo (Lamivudine/Tenofovir Disoproxil Fumarate) Tablet |
| Climara Pro (estradiol/levonorgestrel transdermal system) |
| CLINDAGEL (clindamycin phosphate gel) |
| Clozapine |
| Clozapine |
| Coartem® (Artemether And Lumefantrine) |
| Colcrys (colchicine) tablets |
| Combigan (Brimonidine Tartrate/Timolol Maleate) Ophthalmic Solution |
| Combivent Respimat (Ipratropium/Albuterol) |
| Corlanor (Ivabradine) |
| Cortifoam (Hydrocortisone 10%) Rectal Foam |
| Cosentyx® (Secukinumab) |
| Cotellic (Cobimetinib) |
| CREON (Pancrelipase) Delayed-Release Capsules |

| |
|--|
| Crinone (Progesterone) Gel |
| CUPRIMINE (penicillamine) Capsules |
| CYCLOSET (bromocriptine mesylate tablets) |
| Cyclosporine Capsules Modified |
| Cyclosporine Oral Solution Modified |
| Cymbalta® (Duloxetine Delayed-Release Capsules) |
| Cyramza® (Ramucirumab) Injection |
| Cystagon (Cysteamine) Capsules |
| Daliresp (Roflumilast) |
| Dalvance (Dalbavancin) Lyophilizate |
| Darzalex (Daratumumab) Injection For Iv Infusion |
| Darzalex Faspro (Daraumumab And Hyaluronidase-Fihj) Injection For Subcutaneous Use |
| DAURISMO (glasdegib) |
| Delstrigo™ (Doravirine, Lamivudine, And Tenofovir Disoproxil Fumarate) Tablets, For Oral Use |
| Delzicol (Mesalamine Dr) Capsules |
| DEMSER (metyrosine) Capsules |
| Denavir (Penciclovir) Cream 1% |
| Depakote (Divalproex Sodium) |
| Depen (Penicillamine) Tablets |
| Depo®-Estradiol (Estradiol Cypionate) Injection, USP |
| Depo-Provera® (Medroxyprogesterone Acetate Injectable SUSPension) |
| Detrol La (Tolterodine) |
| Detrol® (Tolterodine Tartrate) Tablets |
| Detrol® La (Tolterodine Tartrate) Extended-Release Capsules |
| Dexilant (dexlansoprazole) DR capsules |
| Dificid® (Fidaxomicin) For Oral SUSPension 40 Mg/mL |
| Dificid® (Fidaxomicin) Tablets |
| Dilantin® (Extended Phenytoin Sodium) Capsules |
| Dipentum (Olsalazine) Capsule |
| DROXIA (hydroxyurea) |
| Duavee™ (Conjugated Estrogens/Bazedoxifene) Tablets |
| DUOBRII (halobetasol propionate and tazarotene 0.01%/0.45%) |
| Duopa (Carbidopa/Levodopa) Enteral SUSPension |
| Durysta (Bimatoprost) Ocular Implant |
| Dymista (Azelastine/Fluticasone) Nasal Spray |
| Edarbi (azilsartan medoxomil) |
| Edarbyclor (azilsartan medoxomil/chlorthalidone) |
| Edurant (Rilpivirine) Tablets |
| EFUDEX (fluorouracil) Topical Cream |
| Elestrin (Estradiol Gel) 0.06% |
| ELIDEL (pimecrolimus) Cream, 1% for Topical Use |
| Eligard (leuprolide) |

| |
|---|
| Eliquis® (Apixaban) |
| ELLENCE (epirubicin) |
| Elmiron (Pentosan Polysulfate Sodium) Capsules |
| EMCYT (estramustine) |
| Emend® (Aprepitant) 80 Mg, 125 Mg Capsules |
| Emend® (Aprepitant) For Oral SUSPension 125 Mg |
| Emend® (Fosaprepitant Dimeglumine) For Injection 150 Mg |
| Emgality® (Galcanezumab-Gnlm) Injection |
| Impliciti® (Elotuzumab) |
| Emsam Transdermal System |
| Enbrel (Etanercept) |
| Engerix-B (Hepatitis B Vaccine) |
| Enspryng (Sonalizumab-Mwge) |
| Entresto™ (Sacubitril/Valsartan) |
| Epipen & Epipen Jr (Epinephrine) Injection |
| Epivir-Hbv (Lamivudine Solution Or Tablets) |
| Epogen (Epoetin Alfa) |
| Erbitux® (Cetuximab) Injection |
| Erivedge (Vismodegib) |
| Erleada (Apalutamide) Tablets |
| Erygel (Erythromycin) Topical Gel 2% |
| Esbriet (Pirfenidone) |
| Estrace (Estradiol) Cream |
| Estring® (Estradiol Vaginal Ring) |
| Evenity (Romosozumab-Aqqg) |
| Evista® (Raloxifene Hydrochloride) Tablet |
| Evoclin (Clindamycin) Foam 1% |
| Evrysdi (Risdiplam) |
| Extavia® (Interferon Beta-1B) |

F-J

| |
|--|
| Faslodex (Fulvestrant) |
| Farxiga (Dapagliflozin) |
| Fasenra (Benralizumab) |
| Fasenra Pen (Benralizumab) |
| Felbatol (Felbamate) |
| Feldene® (Piroxicam) Capsules |
| Ferumoxytol Injection |
| Fetzima (Levomilnacipran) Extended Release Capsules And Titration Pack |
| Fiasp Flextouch (Insulin Aspart) |
| Flovent (Diskus Or HFA) (Fluticasone) |
| Forteo® (Teriparatide Injection) |

| |
|--|
| Fosrenol (lanthanum carbonate) |
| Fragmin® (Dalteparin Sodium) Injection |
| Fulphila (Pegfilgastrim-Jmdb) |
| Fulvestrant Injection, For Intramuscular Use |
| FYARRO (sirolimus albumin-bound) for injection |
| Gabitril (Tigabine Hydrochloride) Tablets |
| Galzin (Zinc Acetate) Capsules |
| Gardasil®9 (Human Papillomavirus 9-Valent Vaccine, Recombinant) |
| Gastrocrom (Cromolyn) Oral Concentrate |
| Gavreto (Pralsetinib) |
| Gazyva (Obinutuzumab) |
| Gelnique (Oxybutynin Chloride 10%) Gel |
| Gengraf Capsules (Cyclosporine, USP [Modified]) |
| Genotropin® (Somatropin) For Injection |
| Gilenya® (Fingolimod) |
| Giltorif (Afatinib) |
| Glatiramer Acetate |
| Glucagen Hypokit |
| Glucagon™ (Glucagon For Injection) |
| Glyxambi (Empagliflozin/Metformin) |
| Granix (Tbo-Filgrastim) Injection |
| Haldol Decanoate (Haloperidol) Im Injection Only |
| Horizant (gabapentin encarbil) |
| Hemlibra (Emcizumab-Kxwh) |
| Heparin Sodium Injection, USP |
| Herceptin (Trastuzumab) |
| Herceptin Hylecta (Trastuzumab And Hyaluronidase-Oysk) |
| Herzuma (Trastuzumab-Pkrb) Injection |
| Humalog® Mix50/50™ (Insulin Lispro Protamine And Insulin Lispro Injectable SUSPension) |
| Humalog® Mix75/25™ (Insulin Lispro Protamine And Insulin Lispro Injectable SUSPension) |
| Humalog® U-100 (Insulin Lispro Injection) |
| Humalog® U-200 (Insulin Lispro Injection) |
| Humatrope® (Somatropin) For Injection |
| Humira (Adalimumab) |
| Humulin® 70/30 (Human Insulin Isophane SUSPension And Human Insulin Injection) |
| Humulin® N (Isophane Insulin Human SUSPension) |
| Humulin® R (Insulin Human Injection) |
| Humulin® R U-500 (Insulin Human Injection) |
| Hycamtin® (Topotecan Hydrochloride) For Injection |
| Hycamtin® (Topotecan) Capsules |
| IBRANCE (Palbociclib) |
| IDAMYCIN (idarubicin) |

| |
|---|
| IDHIFA® (Enasidenib) |
| ILARIS® (Canakinumab) |
| ILEVRO® (Nepafenac SUSPension) |
| Imbruvica (Ibrutinib) Capsules/Tablets |
| Imbruvica (Ibrutinib) |
| Imfinzi (Durvalumab) |
| Imitrex (Sumatriptan Nasal Spray) |
| IMJUDO (tremelimumab-act1) |
| Imlygic (Talimogene) |
| Imogam® Rabies-Ht Immune Globulin, [Human] USP, Heat Treated |
| Imovax® Rabies Vaccine [Human Diploid Cell] |
| Impeklo (Clobetasol) Lotion |
| Incruse Ellipta (Umeclidinium) |
| Infed (Iron Dextran) Injection |
| Inflectra® (Infliximab-Dyyb) For Injection |
| INLYTA (axitinib) |
| Inrebic® (Fedratinib) |
| Inspira (Eplerenone) |
| Intelence (Etravirine) Tablets |
| Intuniv (guanfacine) ER tablets |
| Invega Sustenna, Trinza And Hafyera (Paliperidone Palmitate) Extended-Release Injection |
| Invokamet (Canagliflozin/Metformin) |
| Invokamet Xr (Canagliflozin/Metformin Xr) |
| Invokana (Canagliflozin) |
| Iressa (Gefitinib) |
| Isentress® (Raltegravir) 400 Mg Film-Coated And 25 Mg And 100 Mg Chewable Tablets |
| Isentress® Hd (Raltegravir) 600 Mg Tablets |
| Isentress® Os (Raltegravir) 100 Mg Granules For SUSPension |
| Istodax® (Romidepsin) |
| Jadenu ® (Deferasirox) |
| Jadenu® Sprinkle (Deferasirox) Granules |
| Janumet® (Sitagliptin And Metformin Hci) Tablets |
| Janumet® Xr (Sitagliptin And Metformin Hci Extended-Release) Tablets |
| Januvia® (Sitagliptin) Tablets |
| Jardiance (Empagliflozin) |
| Jemperli (Dostarlimab) |
| Jentadueto & Jentadueto Xr (Linagliptin/Metformin) |
| Jivi (antihemophilic factor recombinant) |
| JUBLIA® (efinaconazole) Topical Solution |
| Jynarque (Tolvaptan) Tablets |

K-O

| |
|--|
| Kadcyla (Ado-Trastuzumab Emtansine) |
| Kaletra (Lopinavir/Ritonavir) |
| Kanjinti (Trastuzumab-Anns) |
| Kazano (alogliptin/metformin) tablets |
| Kerendia (finerenone) |
| Kesimpta® (Ofatumumab) |
| Keytruda® (Pembrolizumab) Injection [Liquid Formulation] 100 Mg |
| Kisqali® Femara® Co-Pack (Ribociclib And Letrozole) Tablets |
| Kisqali® (Ribociclib) |
| Kombiglyze Er (Saxagliptin/Metformin Er) |
| KOVALTRY (antihemophilic factor recombinant) |
| Kyleena (levonorgestrel-releasing intrauterine system) |
| Kynmobi™ (apomorphine hydrochloride) |
| Kyprolis (Carilzomib) |
| Lamictal (Lamotrigine Chewable Or Orally Disintegrating Tablets) |
| Lamictal ODT (Lamotrigine Patient Titration Kits) |
| Lamictal Xr (Lamotrigine Er Or Patient Titration Kit) |
| Lampit (nifurtimox) |
| Lantus® (Insulin Glargine Injection) 100 Units/mL |
| Latuda (lurasidone) |
| Leqvio® (Inclisiran) |
| Levemir (Insulin Detemir) FlexTouch |
| LevoLeucovorin Injection |
| Levoxyl® (Levothyroxine Sodium) Tablets |
| Lexapro (Escitalopram) |
| Lialda (mesalamine) DR tablets |
| Liletta (Levonorgestrel) Intrauterine Contraceptive |
| Lincocin® (Lincomycin) Injection, USP |
| Linzess (Linaclotide) Capsules |
| LOCOID LIPOCREAM |
| LOCOID (hydrocortisone butyrate) Lotion |
| Lo Lestrin Fe |
| Lokelma (Sodium Zirconium Cyclosilicate) |
| LORBRENA (lorlatinib) |
| Lovenox® (Enoxaparin Sodium Injection) |
| Lucentis (Ranibizumab Injection) |
| Lumakras (Sotorasib) |
| Lumigan (Bimatoprost 0.01%) Ophthalmic Solution |
| Lumoxiti (Moxetumomab Pasudotox-Tdffk) |
| Lupron Depot (Leuprolide Acetate For Depot SUSPension) |
| Lupron Depot-Ped (Leuprolide Acetate For Depot SUSPension) |
| Lutathera® (Lutetium Lu 177 Dotatate) |

| |
|---|
| Luxiq (Betamethasonevalerate) Foam |
| LUZU (luliconazole) Cream, 1% for Topical Use |
| Lynparza (Olaparib) |
| Lyumjev™ (Insulin Lispro-Aabc) Injection |
| Malarone (Atovaquone And Proguanil) |
| Mavyret (Glecaprevir/Pibrentasvir) |
| Maxidex® (Dexamethasone SUSPension) |
| Mayzent® (Siponimod) |
| Mekinist® (Trametinib) |
| MEKTOVI (bibimetinib) |
| Menest® (Esterified Estrogens) Tablets, USP |
| Menostar (estradiol transdermal system) |
| Menquadfi® (Meningococcal [Groups A, C, Y, W] Conjugate Vaccine) |
| MEPHYTON (phytonadione) Vitamin K1 Tablets |
| Mepron (Atovaquone SUSPension) |
| Miacalcin Injection (calcitonin) |
| Mirena (levonorgestrel-releasing intrauterine system) |
| M-M-R® II (Measles, Mumps, And Rubella Virus Vaccine Live) |
| Monovisc (High Molecular Weight Hyaluronan) Injection |
| Monurol (Fosfomycin Tromethamine) Oral Granules |
| Motegrity (prucalopride) tablets |
| MOVIPREP (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution) |
| Mozobil® (Plerixafor Injection) |
| Multaq® (Dronedarone) Tablets |
| Muse (Alprostadil) Urethral |
| Mvasi (Bevacizumab-Awwb) |
| Mycobutin® (Rifabutin) Capsules, USP |
| Mydayis (amphetamine) ER capsules |
| MYLOTARG (gemtuzumab) |
| Namenda And Namenda Xr (Memantine) |
| Namzaric (Memantine Extended Release And Donepezil) |
| Narelle |
| Natazia (estradiol valerate and estradiol valerate/dienogest) |
| Nesina (alogliptin) tablets |
| Neulasta (Pegfilgrastim) |
| Neupogen (Filgrastim) |
| Nevanac® (Nepafenac SUSPension) |
| Nexavar (sorafenib) |
| Nicotrol® (Nicotine) |
| NIVESTYM (filgrastim-aafi) |
| NORITATE (metronidazole cream) Cream, 1% for Topical Use Only |

| |
|---|
| Norpace® (Disopyramide Phosphate) |
| Norvir (Ritonavir) Tablets And Oral Solution |
| Novlog Mix 70/30 (Insulin Aspart Protamine And Insulin Aspart) Flexpen |
| Novolin 70/30 (Insulin Nph And Insulin R Mix) Vial |
| Novolin N Vial (Insulin Nph) |
| Novolin R Vial (Insulin Regular) |
| Novolog (Insulin Aspart) Flexpen |
| Noxafil® (Posaconazole) Delayed-Release Tablets 100 Mg |
| Noxafil® (Posaconazole) Oral SUSPension, 40 Mg/Ml |
| Nplate (Romiplostim) |
| Nubeqa (darolutamide) |
| Nucala (Mepolizumab) |
| Nulox® (Belatacept)) |
| NUPLAZID (pimavanserin) |
| Nuvigil (Armodafinil) Tablets [C-IV] |
| Nymalize (nimodipine oral solution) |
| NYVEPRIA (pegfilgrastim-apgf) |
| Ocrevus (Orelizumab) |
| Ofev (Nintedanib) |
| Ogivri* (Trastuzumab-Dkst) |
| Olumiant® (Baricitinib) Tablets |
| Olux (Clobetasol) Foam 0.05% |
| Olux-E (Clobetasol) Foam 0.05% |
| Omnitrope® Somatropin (RdnA Origin) |
| ONEXTON (clindamycin phosphate and benzoyl peroxide) Gel, 1.2% or 3.75% for Topical |
| Onglyza (Saxagliptin) |
| Onureg® (Azactidine Tablets) |
| Opdivo® (Nivolumab) |
| Opdualag™ (Nivolumab And Relatlimab – Rmbw) |
| Opsumit (Macitentan) Tablets |
| Orencia® (Abatacept) |
| Oriahnn (Elagolix/Estradiol/Norethindrone) |
| Orilissa (Elagolix) Tablets |
| Orthovisc (High Molecular Weight Hyaluronan) Injection |
| Oseni (alogliptin/pioglitazone) tablets |
| Otezla (Apremilast) |
| Ozempic (Semaglutide) Injection |
| Ozurdex (Dexamethasone) Ocular Implant |
| P-T |
| Parsabiv (Etelcalcetide) |
| Pegasys (Peginterferon Alfa-2A) |

| |
|---|
| Pentacel® Diphteria And Tetanus Toxoids And Acellular Pertussis Adsorbed, Inactivated Poliovirus And Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine |
| Pentasa (mesalamine) ER capsules |
| Perforomist (Formoterol Fumarate) Inhalation Solution |
| Perjeta (Pertuzumab) |
| Phesgo (Pertuzumab, Trastuzumab, And Hyaluronidase-Zzxf) |
| Pifeltro™ (Doravirine) Tablets, For Oral Use |
| Piqray® (Alpelisib) |
| PLENVU® (PEG 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride), Powder for oral solution |
| Pluvicto® (177Lu-Psma-617) |
| Pneumovax®23 (Pneumococcal Vaccine Polyvalent) |
| Polivy (Polatuzumab Vedotin-Piiq) |
| Pomalyst® (Pomalidomide) |
| Ponvory (Ponesimod) |
| Portrazza® (Necitumumab) Injection |
| Pradaxa (Dabigatran) |
| Praluent (alirocumab) |
| Pred Forte (Prednisolone Acetate) Ophthalmic SUSPension |
| Premarin® (Conjugated Estrogens) Tablets, USP (Conjugated Estrogens Tablets |
| Premarin® (Conjugated Estrogens) Vaginal Cream (Conjugated Estrogens) Vaginal Cream |
| Premphase® (Conjugated Estrogens Plus Medroxyprogesterone Acetate) Tablets |
| Prempro® (Conjugated Estrogens/Medroxyprogesterone Acetate) Tablets |
| Pretomanid Tablet |
| Prevacid (lansoprazole) ODT tablets |
| Prevnar 13® Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria Crm197 Protein] |
| Prevymis™ (Letermovir) 240 Mg Tablets |
| Prezcobix (Darunavir/Cobicistat) |
| Prezista (Darunavir) |
| Priftin® (Rifapentine) Tablets |
| Pristiq® (Desvenlafaxine) Extended-Release Tablets |
| Proair HFA (Albuterol Sulfate) Inhalation Aerosol |
| Proair Respclick (Albuterol Sulfate) Inhalation Aerosol |
| Procrit (Epoetin Alfa) |
| Proctofoam Hc (Hydrocortisone Acetate 1% & Pramoxine 1%) |
| Proglycem (Diazoxide) Oral SUSPension |
| Prolia (Denosumab) |
| Promacta® (Eltrombopag) |
| Prozac® (Fluoxetine Capsules) |
| Pulmicort Flexhaler (Budesonide) |
| Pulmozyme (Dornase Alfa) Inhalation Solution |
| Pylera (Bismuth Subcitrate Potassium, Metronidazole, And Tetracycline) Capsules |
| QNASL (Beclomethasone) Nasal Aerosol |

| |
|---|
| QTERN (Dapagliflozin/Saxagliptin) |
| QULIPTA (Atogepant) Tablets |
| QVAR Redihaler (Beclomethasone Dipropionate HFA) Inhalation Aerosol |
| Rapaflo (Silodosin) Capsules |
| Rapamune® (Sirolimus) |
| Reblozyl® (LUSPatercept-Aamt) |
| Recarbrio™ (Imipenem, Cilastatin, And Relebactam) For Injection, For Intravenous Use |
| Recombivax Hb® [Hepatitis B Vaccine (Recombinant)] |
| Rectiv (Nitroglycerin) Ointment |
| Relenza (Zanamivir Inhalation Powder) |
| RELISTOR (methylnaltrexone bromide) |
| Relpax (Eletriptan) |
| Relpax® (Eletriptan Hydrobromide) Tablets |
| Remicade (Infliximab) Iv Infusion |
| RENOVA (tretinooin cream) 0.02% for Topical Use, Pump |
| Repatha (Evolocumab) |
| Restasis (Cyclosporine) Ophthalmic Emulsion |
| RETACRIT (epoetin alfa-epbx) |
| Retevmo™ (Selpercatinib) Capsules |
| RETIN-A CREAM 45 gm 0.025% or 0.05% or 0.1% |
| RETIN-A GEL 45 gm 0.01% or 0.025% |
| RETIN-A MICRO (tretinooin) Gel Microsphere for Topical Use 0.06% or 0.08% |
| Revatio (Sildenafil) |
| Revlimid® (Lenalidomide) |
| Rexulti (Brexpiprazole) Tablets |
| Revvow® (Lasmiditan) Tablets C-V |
| Riabni (Rituximab-Arrx) |
| Rinvoq (Upadacitinib) |
| Risperdal Consta (Risperidone) Long-Acting Injection |
| Rituxan (Rituximab) For Granulomatosis With Polyangiitis (Gpa), Microscopic Polyangiitis (Mpa) Or Pemphigus Vulgaris (Pv) |
| Rituxan (Rituximab) For Oncology |
| Rituxan (Rituximab) For Rheumatoid Arthritis |
| Rituxan Hycela (Rituximab/Hyaluronidase Human) |
| Rowasa (Mesalamine) Rectal SUSPension |
| Rozerem (ramelteon) tablets |
| Rozlytrek (Entrectinib) |
| RUXIENCE (rituximab-pvvr) |
| Rybelsus (Semaglutide) Tablets |
| Rybrevant (Amivantamab-Vmjh) |
| Rydapt® (Midostaurin) |
| SAFYRAL (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets) |

| |
|--|
| Samsca (Tolvaptan) |
| Sandostatin Lar® Depot (Octreotide Acetate) |
| Saphnelo (Anifrolumab-Fnia) |
| Saphris (Asenapine Maleate) Sublingual Tablet |
| Savella (Milnacipran) Tablets |
| Scemblix® (Asciminib) Tablets |
| Semglee (Insulin Glargine) |
| Sensipar (Cinacalcet) |
| Serevent (Diskus) (Salmeterol) |
| Sf Rowasa (Mesalamine) Rectal SUSPension |
| Shingrix (Zoster Vaccine) |
| SILIQ (brodalumab) injection, for subcutaneous use, 210 mg/1.5 mL solution |
| Simponi (Golimumab) Injection |
| Sirturo (Bedaquiline) Tablets |
| Skelaxin® (Metaxalone) Tablets |
| Skyla (levonorgestrel-releasing intrauterine system) |
| Skyrizi (Risankizumab-Rzaa) |
| Soliqua® 100/33 (Insulin Glargine & Lixisenatide) Injection 100 Units/mL And 33 Mcg/mL |
| SOLODYN (minocycline HCl) Extended Release Tablets for Oral Use 55 mg or 80 mg or 105 mg |
| Somavert® (Pegvisomant) For Injection |
| Sotylyze (sotalol oral solution) |
| SOTYKTU (deucravacitinib) |
| Spiriva Handihaler Or Respimat (Tiotropium) |
| Sporanox (Itraconazole) Capsules And Oral Solution |
| Spravato (Esketamine) Nasal Spray [CIII] |
| Sprycel® (Dasatinib) |
| Stelara (Ustekinumab) For Subcutaneous Or Iv Use |
| Stiolto Respimat (Tiotropium/Olodaterol) |
| Stivarga (regorafenib) |
| Strattera® (Atomoxetine) Capsules |
| Strattice (Reconstructive Tissue Matrix) |
| Striverdi Respimat (Olodaterol) |
| Stromectol® (Ivermectin) Tablets |
| Susvimo (Ranibizumab) |
| SUTENT (sunitinib) |
| Symbicort (Budesonide/Formoterol) |
| Symbax® (Olanzapine And Fluoxetine) Capsules |
| Symlin (Pramlintide) |
| Symtuza (Darunavir, Cobicistat, Emtricitabine, Tenofovir Alafenamide) Tablets |
| Synarel® (Nafarelin Acetate) Nasal Solution |
| Synjardy & Synjardy Xr (Empagliflozin/Metformin) |
| Synribo (Omacetaxine) For Injection |

| |
|---|
| Synthroid (Levothyroxine Sodium) Tablets |
| SYPRINE (trientine hydrochloride) Capsules |
| Tabrecta™ (Capmatinib) |
| Tafinlar® (Dabrafenib) |
| Tagrisso (Osimertinib) |
| Taltz® (Ixekizumab) Injection |
| TALZENNA (talazoparib) |
| TARGRETIN (bexarotene) |
| Tasigna® (Nilotinib) |
| TASMAR (tolcapone) Tablets |
| Tecentriq (Atezolizumab) |
| Teflaro (Ceftaroline Fosamil) Powder For Injection |
| Tenivac® (Tetanus And Diphtheria Toxoids Adsorbed) |
| TETRIX CREAM |
| Thalomid® (Thalidomide) |
| Thymoglobulin® [Anti-Thymocyte Globulin (Rabbit)] |
| Tikosyn® (Dofetilide) Capsules |
| TNKase (Tenecteplase) |
| Tobi (Tobramycin) Ampules Or Podhalers |
| Tobradex® (Ophthalmic Ointment) |
| TORISEL (temsirolimus) |
| Toujeo® (insulin glargine injection) 300 Units/mL (1.5 mL or 3.0 mL pens) |
| Toviaz® (Fesoterodine Fumarate) Extended-Release Tablets |
| Tracleer (Bosentan) |
| Tradjenta (Linagliptin) |
| TRAZIMERA (trastuzumab-qyyp) |
| Treanda (Bedamustine) For Injection |
| Trecator® (Ethionamide) Tablets |
| Tremfya (Guselkumab) For Subcutaneous Use |
| Tresiba (Insulin Degludec) FlexTouch |
| Triesence® (Triamcinolone Acetonide Injectable SUSPension) |
| Trijardy Xr (Empagliflozin/Linagliptin/Metformin) |
| Trintellix (vortioxetine tablets) |
| Triptodur (triptorelin) |
| Trisenox (Arsenite Trioxide) Injection |
| TRULANCE (plecanatide) 3 mg Tablets |
| Trulicity® (Dulaglutide) Injection |
| Trumenba® (Meningococcal Group B Vaccine) |
| Trusopt® (Dorzolamide Hydrochloride Ophthalmic Solution) 2% |
| Truxima (Rituximab-Abbs) Injection |
| Tygacil® (Tigecycline) For Injection |
| Tykerb® (Lapatinib) |

[TYMLOS \(abaloparatide\) injection](#)

U-Z

[Ubrelvy \(Ubrogepant\) Tablets](#)

[UCERIS \(budesonide\) Rectal Foam](#)

[Uptravi \(Selexipag\)](#)

[Vabysmo \(Faricimab-Svoa\)](#)

[Vaqta® \(Hepatitis A Vaccine, Inactivated\)](#)

[Varivax® \(Varicella Virus Vaccine Live\)](#)

[Vaxneuvance™ \(Pneumococcal 15-Valent Conjugate Vaccine\)](#)

[Vectibix \(Panitumumab\)](#)

[Veletri \(Epoprostenol\)](#)

[Venclexta \(Venetoclax Tablets\)](#)

[Venclexta \(Venetoclax\) Tablets](#)

[Ventavis \(Iloprostol\)](#)

[Verquvo™ \(Vericiguat\) 2.5 Mg, 5 Mg, 10 Mg Tablets](#)

[Verzenio® \(Abemaciclib\) Tablets](#)

[Veltassa \(patiromer\)](#)

[Vfend® \(Voriconazole\)](#)

[Viberzi \(Eluxadoline\)](#)

[Victoza \(Liraglutide\) Pen](#)

[Vidaza® \(Azacitidine For Injection\)](#)

[Viibryd \(Vilazodone\)](#)

[Vijoice® \(Alpelisib\)](#)

[Viokace \(Pancrelipase\) Tablets](#)

[Viramune Xr \(Nevirapine\)](#)

[VITRAKVI \(Larotrectinib\)](#)

[VIZIMPRO \(dacaomitinib\)](#)

[Votrient® \(Pazopanib\)](#)

[Vraylar \(Cariprazine\) Capsules](#)

[Vyndaqel® \(Tafamidis Meglumine\) Capsules](#)

[Vyvanse \(lisdexamfetamine\) capsules and tablets](#)

[Welireg™ \(Belzutifan\) 40 Mg Tablets](#)

[Wixela \(Fluticasone/Salmeterol\)](#)

[XALKORI \(crizotinib\)](#)

[Xanax® CIV \(Alprazolam\) Tablets](#)

[Xarelto \(Rivaroxaban\) Tablets Or Oral Solution](#)

[Xeljanz® \(Tofacitinib\) Oral Solution](#)

[Xeljanz® \(Tofacitinib\) Tablets](#)

[Xeljanz® Xr \(Tofacitinib\) Extended-Release Tablets](#)

[Xeloda \(Capecitabine\)](#)

| |
|---|
| Xen (Gel Stent) |
| Xgeva (Denosumab) |
| XIFAXAN (rifaximin) Tablets, for Oral Use, 550 mg |
| Xigduo Xr (Dapagliflozin/Metformin Er) |
| Xiidra® (Lifitegrast Ophthalmic Solution) |
| Xofigo (radium Ra 223 dichloride) |
| Xolair (Omalizumab) |
| Xulane (Norelgestromin And Ethynodiol Transdermal System) |
| Xultophy (Insulin Degludec & Liraglutide) Pen |
| Xyntha® Antihemophilic Factor (Recombinant) |
| Yervoy® (Ipilimumab) |
| Yondelis (Trabectedin) For Iv Infusion |
| Yupelri (Re Gefitinib) |
| Zarontin® (E ethosuximide) |
| Zarxio™ (Filgrastim-Sndz) |
| ZELAPAR (selegiline hydrochloride) Orally Disintegrating Tablets |
| Zelboraf (Vemurafenib) |
| Zenpep (Pancrelipase) Delayed Release Capsule |
| Zepatier® (Elbasvir And Grazoprevir) |
| Zeposia® (Ozanimod) |
| Zerbaxa™ (Ceftolozane And Tazobactam) For Injection For Intravenous Use |
| ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel 60 g tube |
| Ziextenza® (Pegfilgrastim-Bmez) |
| Zinplava™ (Bezlotoxumab) Injection 25 Mg/mL |
| ZIRABEV (bevacizumab-bvzr) |
| Zolinza® (Vorinostat) 100 Mg Capsules |
| ZYCLARA (imiquimod) cream 3.75%, for Topical Use 7.5 g Pump Box of 28 Packets |
| Zykadia® (Ceritinib) |
| Zynlonta (loncastuximab tesirine) |
| Zyprexa® (Olanzapine) Tablet |
| Zyprexa® Zydis® (Olanzapine) Tablet |
| Zytiga (Abiraterone) Tablets |
| Zyvox® (Linezolid) |

| Manufacturer | Income documentation required | Medication delivery | FPL cutoff (%) or income threshold for single person(\$) | FPL cutoff 2 | FPL cutoff 3 |
|--------------|----------------------------------|---------------------|--|--------------|--------------|
| AADI | No | Office | 400 | | |
| AbbVie | No | Home | \$81,150 | | |
| Acadia | Application through office staff | Home | Any for uninsured | | |
| ADC | No | Home | 550 | | |
| Amgen | No | Home | 500 | | |

| | | | | | |
|----------------------------|-------------------|----------------|----------|-----|-----|
| Arbor | Yes | Home | 200 | 300 | |
| AstraZeneca | No | Home | 300 | 500 | |
| Bausch Health | No | Home or office | 300 | 400 | 500 |
| Boehringer Ingelheim | No | Home | 250 | | |
| Bristol Myers Squibb | No-but encouraged | Home | 300 | | |
| GlaxoSmithKline (GSK) | No | Home | 250 | | |
| Johnson & Johnson | No | Home | 300 | 400 | 600 |
| Lilly | No | Home | 300 | 400 | 500 |
| Merck | No | Home | 400 | | |
| MyPraluent | No-but encouraged | Home | 300 | | |
| Mylan (Viatris) | Yes | Home | 400 | 500 | |
| Nestle Health | Yes | Office | 400 | | |
| Novartis | No | Home | \$70,000 | | |
| Novo Nordisk | No | Office | 400 | | |
| Otsuka | Yes | Home | 300 | 700 | |
| Pfizer | Yes | Office | \$49,960 | 400 | |
| Pfizer Oncology | No | Home | 500 | | |
| Radius | No-SSN acceptable | Home | 300 | | |
| Roche (Genentech) | No | Home | \$75,000 | | |
| Sanofi | No | Office | 400 | | |
| Sunovion | Yes | Home | 300 | | |
| TAKEDA | Yes | Home | 500 | | |
| TEVA | No | Home | 300 | 500 | |
| Tolmar | Yes | Home | 500 | | |
| Veltassa | Yes | Home | 500 | | |
| FPL=federal poverty limit | | | | | |
| SSN=social security number | | | | | |

Programs that do NOT provide automatic refills:

AbbVie, BAUSCH Health, Boehringer Ingelheim, GSK, Novartis, Pfizer

Programs that needle request needs indicated:

Novo Nordisk (Lilly does NOT include needles)

Programs that require separate prescription be sent:

Arbor, GSK, Novartis

Programs that require applications mailed in:

Merck

Programs that send pharmacy card with ID, BIN, and Rx Group instead of medication itself:

Janssen for Xarelto

Programs that require wet signature (with pen, no e-signature accepted):

Lilly Cares, Boehringer Ingelheim (BI Cares)

| Income thresholds based on federal poverty limit (FPL) ^A 2022 | | | | | | | | |
|--|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Household size | 100% (\$) | 133% (\$) | 150% (\$) | 200% (\$) | 250% (\$) | 300% (\$) | 400% (\$) | 500% (\$) |
| 1 | 13,590 | 18,075 | 20,385 | 27,180 | 33,975 | 40,770 | 54,360 | 67,950 |
| 2 | 18,310 | 24,352 | 27,465 | 36,620 | 45,775 | 54,930 | 73,240 | 91,550 |
| 3 | 23,030 | 30,630 | 34,545 | 46,060 | 57,575 | 69,090 | 92,120 | 115,150 |
| 4 | 27,750 | 36,908 | 41,625 | 55,500 | 69,375 | 83,250 | 111,000 | 138,750 |
| 5 | 32,470 | 43,185 | 48,705 | 64,940 | 81,175 | 97,410 | 129,880 | 162,350 |
| 6 | 37,190 | 49,463 | 55,785 | 74,380 | 92,975 | 111,570 | 148,760 | 185,950 |
| 7 | 41,910 | 55,740 | 62,865 | 83,820 | 104,775 | 125,730 | 167,640 | 209,550 |
| 8 | 46,630 | 62,018 | 69,945 | 93,260 | 116,575 | 139,890 | 186,520 | 233,150 |
| Each additional | 4,720 | 6,278 | 7,080 | 9,440 | 11,800 | 14,160 | 18,880 | 23,600 |

A: Federal poverty limits are subject to change on an annual basis

Medications with PAP per drug manufacturer

AADIAssist Patient Assistance Program

Eligibility

US resident

$\leq 400\%$ FPL

**Uninsured or
lack of
coverage of
medication**

| Household size | Annual household income (\$) threshold ($\leq 400\%$ FPL) |
|-----------------------|---|
| 1 | 54,360 |
| 2 | 73,240 |
| 3 | 92,120 |
| 4 | 111,000 |
| 5 | 129,880 |
| ≥ 5 | Add 4,720 for each additional person |

Medications eligible for assistance

FYARRO (sirolimus albumin bound) for injection

- Income information MAY be required (US federal tax return, social security income statement, recent pay stub)
- Medication is sent directly to prescriber office

AbbVie Assist (usually reviewed within 2 business days)

Eligibility

US resident

**At or below
income
threshold**

**Provide proof
of income**

| Household size | Annual household income (\$) threshold |
|-----------------|---|
| 1 | 81,540 |
| 2 | 109,860 |
| 3 | 138,180 |
| 4 | 166,500 |
| ≥5 | Add 28,320 for each additional person |
| Proof of income | Most recent federal tax form, W2, or social security statements |

Medications eligible for assistance

[Acuvail \(ketorolac tromethamine\) ophthalmic solution](#)[&]

[AeroChamber Plus Flow-Vu](#)^{**}

[Alloderm](#)[%]

[Alphagan P \(brimonidine tartrate\) ophthalmic solution](#)[&]

[Armour Thyroid \(thyroid tablets, USP\) tablets](#)^{**}

[Avycaz \(avibactam-ceftazidime\)](#)[#]

[BOTOX \(onabotulinumtoxinA\)](#)

[Bystolic \(nebivolol\) tablets](#)^{**}

[Canasa \(mesalamine\) suppository](#)^{**}

[Carafate \(sucralfate\) oral sUSPension](#)^{**}

[Combigan \(brimonidine tartrate/timolol maleate\) ophthalmic solution](#)[&]

[CREON \(Pancrelipase\) delayed-release capsules](#)⁺

[Crinone \(progesterone\) gel](#)^{**}

[Dalvance \(dalbavancin\) lyophilizate](#)[#]

[Delzicol \(mesalamine DR\) capsules](#)^{**}

[Depakote \(divalproex sodium\)](#)^{\$}

[Duopa \(carbidopa/levodopa\) enteral sUSPension](#)^{\$}

[Durysta \(Bimatoprost\) ocular implant](#)[&]

[Estrace \(estradiol\) cream](#)^{**}

[Fetzima \(Levomilnacipran\) extended release capsules and titration pack](#)^{**}

[Gelnique \(oxybutynin chloride 10%\) gel](#)^{**}

[GENGRAF capsules \(cyclosporine, USP \[MODIFIED\]\)](#)^{**}

[HUMIRA \(adalimumab\)](#)^{\$}

[IMBRUVICA \(ibrutinib\)](#)^{\$}

[Infed \(iron dextran\) injection](#)^{**}

[KALETRA \(lopinavir/ritonavir\)](#)^{**}

[Lexapro \(escitalopram\)](#)^{**}

[Liletta \(levonorgestrel\) intrauterine contraceptive](#)[^]

[Linzess \(linaclotide\) capsules](#)⁺

[Lo Lestrin fe](#)[^]

[Lumigan \(Bimatoprost 0.01%\) ophthalmic solution](#)[&]

[Lupron Depot-Ped \(leuprolide acetate for depot sUSPension\)](#)^{\$}

[Lupron Depot \(leuprolide acetate for depot sUSPension\)](#)^{\$}

[MAVYRET \(Glecaprevir/Pibrentasvir\)](#)^{\$}

| | |
|---|----|
| Monurol (Fosfomycin tromethamine) oral granules | ** |
| Namenda and Namenda XR (memantine) | ** |
| Namzaric (memantine extended release and donepezil) | ** |
| NATRELLE | % |
| NORVIR (ritonavir) tablets and oral solution | ** |
| Oriahnn (Elagolix/estradiol/norethindrone) | ^ |
| ORILISSA (Elgaolix) tablets | ^ |
| Ozurdex (dexamethasone) ocular implant | & |
| Pred Forte (prednisolone acetate) ophthalmic sUSPension | ** |
| Pylera (bismuth Subcitrate potassium, metronidazole, and tetracycline) capsules | ** |
| Qulipta (Atogepant) tablets | ** |
| Rapaflo (silodosin) capsules | ** |
| Rectiv (nitroglycerin) ointment | ** |
| Restasis (cyclosporine) ophthalmic emulsion | & |
| RINVOQ (upadacitinib) | \$ |
| Saphris (asenapine maleate) sublingual tablet | ** |
| Savella (milnacipran) tablets | ** |
| SKYRIZI (Risankizumab-rzaa) | \$ |
| STRATTICE (reconstructive tissue matrix) | % |
| Synthroid (levothyroxine sodium) tablets | ** |
| Teflaro (ceftaroline fosamil) powder for injection | # |
| Ubrelvy (ubrogepant) tablets | ** |
| Venclexta (venetoclax) tablets | \$ |
| Viberzi (eluxadoline) | + |
| Viibryd (vilazodone) | ** |
| Vraylar (cariprazine) capsules | ** |
| Xen (gel stent) | & |

**Use the “AbbVie Assist General Medication Application”

+Use the “AbbVie Assist GI medication application”

\$ Has individual application

^Use the “AbbVie Assist Women’s health application”

&Use the “AbbVie Eye Care application”

% Use the “AbbVie Assist ALLERGAN AESTHETICS medication application”

Use the “AbbVie Assist ANTIBIOTIC medication application”

Contact info-Phone: 1-800-222-6885 Fax: 1-866-898-1473

[Acadia Connect](#)

Eligibility

US resident

Any income

Uninsured

Medications eligible for assistance

[NUPLAZID \(pimavanserin\)](#)

1. Patient must call 1-844-737-2233 or enroll online.
2. Acadia connect will contact provider office and provide applications to be completed (patient and provider have portion to complete)
3. Once application is approved, patient will be provided medication for 12 months
 - a. After 12 months, program attempts to have patient enrolled in prescription drug plan

[ADC Patient Support](#)

Eligibility

US resident

<550% FPL

Uninsured or
underinsured

- Underinsured is deemed as paying $\geq 20\%$ out of pocket for medication

Medications eligible for assistance

[Zynlonta \(loncastuximab tesirine\)](#)

AMGEN safety net program

Eligibility

US resident > 6 months

<500% FPL

Uninsured or plan excludes AMGEN product

| Household size | Annual household income (\$) threshold (<500% FPL) |
|----------------|--|
| 1 | 67,950 |
| 2 | 91,550 |
| 3 | 115,150 |
| 4 | 138,750 |
| ≥5 | Click for FPL for household larger than 5 or add 23,600 per each additional person |

- a. Medicare patients must demonstrate inability to afford medication, ineligible for Medicaid, do not have other financial options
- b. Does **NOT** specify that income needs provided but states income may be asked to be provided
- c. Requires Medicare Part D recipients to apply through [HealthWell foundation](#) first

Medications eligible for assistance

[Aimovig \(erenumab\)](#)

[ARANESP \(darbepoetin alfa\)](#)

[AVSOLA \(infliximab-axxq\)](#)

[BLINCYTO \(blinatumomab\)](#)

[Corlanor \(ivabradine\)](#)

[Enbrel \(etanercept\)](#)

[Epogen \(epoetin alfa\)](#)

[EVENITY \(romosozumab-aqqg\)](#)

[IMLYYGIC \(talimogene\)](#)

[KANJINTI \(trastuzumab-anns\)](#)

[Kyprolis \(carilzomib\)](#)

[LUMAKRAS \(sotorasib\)](#)

[MVASI \(bevacizumab-awwb\)](#)

[Neulasta \(pegfilgrastim\)](#)

[NEUPOGEN \(filgrastim\)](#)

[Nplate \(romiplostim\)](#)

[Otezla \(apremilast\)](#)

[Parsabiv \(etelcalcetide\)](#)

[Prolia \(denosumab\)](#)

| |
|---|
| Repatha (evolocumab) |
| RIABNI (rituximab-arrx) |
| Sensipar (cinacalcet) |
| Vectibix (panitumumab) |
| XGEVA (denosumab) |

Contact info varies by program, see individual medication application for phone and fax

Arbor Pharmaceuticals

Eligibility

US resident

<200 - 300% FPL

Uninsured
or Medicare
A&B

| Household size | Annual household income (\$) threshold | |
|----------------|---|-----------------------------|
| | <u>≤ 200% FPL</u> | <u>BiDil (<300% FPL)</u> |
| 1 | 27,180 | 40,770 |
| 2 | 36,620 | 54,930 |
| 3 | 46,060 | 69,090 |
| 4 | 55,500 | 83,250 |
| <u>≥5</u> | Call Arbor Pharmaceuticals 877-438-9759 | |

- Medicare Part D Applicants: If Part D does not allow or pay for any part of medication, will be viewed as having no insurance. Being in the donut hole does not qualify.
- Requires proof of income
- Separate prescription needs faxed

Medications eligible for assistance

BiDil (isosorbide dinitrate/hydralazine)

Edarbi (azilsartan medoxomil)

Edarbyclor (azilsartan medoxomil/chlorthalidone)

Horizant (gabapentin encarbil)

Nymalize (nimodipine oral solution)

Sotyrlize (sotalol oral solution)

Triptodur (triptorelin)

Contact info-**Phone:** 877-438-9759 **Fax:** 877-619-6574

AstraZeneca AZ&ME program

Eligibility

US resident

<300-500% FPL

Uninsured or
Medicare

AZ&ME cutoffs: 500% FPL for specialty medications, 300% for all others

| Household size | Annual household income (\$) threshold | |
|----------------|--|-----------------------------|
| | Group 1 ($\leq 300\%$ FPL) | Group 2 ($\leq 500\%$ FPL) |
| 1 | 40,770 | 67,950 |
| 2 | 54,930 | 91,550 |
| 3 | 69,090 | 115,150 |
| 4 | 83,250 | 138,750 |
| ≥ 5 | Call AZ&ME 1-800-292-6363 | |

If patient has spent 10% of annual household income out of pocket on medical expenses in last 12 months, can submit documentation and still apply*

If patient is <150% FPL, program requires patient apply to Medicaid. If Medicaid denies claim, can send in denial letter from Medicaid and still apply. Can be granted 3 month supply while Medicaid decision is pending

- i. Electronic income verification will occur, does not affect credit score
 - 1. Some instances occur that the program wants proof of income requiring:
 - a. Most recent federal tax return
 - b. W2 or 1099
 - c. Social security income yearly benefits statement
 - 2. If income is zero, a letter from healthcare provider, family member, or patient can explain the financial situation and be submitted

Medication eligible for assistance

| Insurance Group | Medication name |
|-----------------|---|
| 1 | BEVESPI AEROSPHERE (glycopyrrolate/formoterol) |
| 1 | BREZTRI AEROSPHERE (budesonide/glycopyrrolate/formoterol) |
| 1 | BRILINTA (ticagrelor) |
| 1 | BYDUREON (exenatide extended release) |
| 1 | BYETTA (exenatide) |
| 2 | CALQUENCE (acalabrutinib) |
| 1 | DALIRESP (roflumilast) |
| 1 | FARXIGA (dapagliflozin) |
| 2 | FASENRA (benralizumab) |

| | |
|---|--|
| 2 | FASENRA pen (benralizumab) |
| 2 | FASLODEX (fulvestrant) |
| 2 | IMFINZI (durvalumab) |
| 2 | IMJUDO (tremelimumab-actl) |
| 2 | IRESSA (gefitinib) |
| 1 | KOMBIGLYZE ER (saxagliptin/metformin ER) |
| 1 | LOKELMA (sodium zirconium cyclosilicate) |
| 2 | LUMOXITI (moxetumomab pasudotox-tdffk) |
| 2 | LYNPARZA (Olaparib) |
| 1 | ONGLYZA (saxagliptin) |
| 1 | PULMICORT FLEXHALER (budesonide) |
| 1 | QTERN (dapagliflozin/saxagliptin) |
| 2 | SAPHNELO (anifrolumab-fnia) |
| 1 | SYMBICORT (budesonide/formoterol) |
| 1 | SYMLIN (pramlintide) |
| 2 | TAGRISSO (Osimertinib) |
| 1 | XIGDUO XR (dapagliflozin/metformin ER) |

Contact info-Phone: 1-800-292-6363 Fax for non-specialty medications: 1-877-239-0867

BAUSCH HEALTH

Eligibility

US resident

\leq 300-500% FPL

Uninsured or
Medicare

| Household size | Annual household income (\$) threshold | | |
|----------------|--|----------------------------|----------------------------|
| | Group 1 (\leq 300% FPL) | Group 2 (\leq 400% FPL) | Group 3 (\leq 600% FPL) |
| 1 | 40,770 | 54,360 | 81,540 |
| 2 | 54,930 | 73,240 | 109,860 |
| 3 | 69,090 | 92,120 | 138,180 |
| 4 | 83,250 | 111,000 | 166,500 |
| \geq 5 | Click here for family's > 5 persons | | |

- For Medicare patients that have coverage of the requested medication, they may appeal for evaluation of eligibility, reviewed on a case-by-case basis

Medications eligible for assistance

| Income group | Medication name |
|--------------|---|
| 1 | ACANYA® (clindamycin phosphate and benzoyl peroxide) Gel, 1.2% or 2.5%, for Topical |
| 1 | ALDARA Cream 5% |
| 1 | ANCOBON (flucytosine) capsules |
| 1 | APLENZIN (bupropion hydrobromide) Extended-Release Tablets |
| 1 | ARAZLO (tazarotene) Lotion, 0.045% |
| 1 | ATOPICLAIR Nonsteroidal Cream 100 g Tube |
| 1 | BENZAMYCIN GEL |
| 1 | BIAFINE |
| 1 | BRYHALI (halobetasol propionate) Lotion |
| 1 | CARAC (fluorouracil cream) |
| 1 | CLINDAGEL (clindamycin phosphate gel) |
| 3 | CUPRIMINE (penicillamine) Capsules |
| 1 | CYCLOSET (bromocriptine mesylate tablets) |
| 3 | DEMSER (metyrosine) Capsules |
| 1 | DUOBRII (halobetasol propionate and tazarotene 0.01%/0.45%) |
| 1 | EFUDEX (fluorouracil) Topical Cream |
| 1 | ELIDEL (pimecrolimus) Cream, 1% for Topical Use |
| 1 | JUBLIA® (efinaconazole) Topical Solution |
| 1 | LOCOID LIPOCREAM |
| 1 | LOCOID (hydrocortisone butyrate) Lotion |
| 1 | LUZU (luliconazole) Cream, 1% for Topical Use |
| 1 | MEPHYTON (phytonadione) Vitamin K1 Tablets |
| 1 | MOVIPREP (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution) |
| 1 | NORITATE (metronidazole cream) Cream, 1% for Topical Use Only |
| 1 | ONEXTON (clindamycin phosphate and benzoyl peroxide) Gel, 1.2% or 3.75% for Topical |
| 1 | PLENUVU® (PEG 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride), Powder for oral solution |
| 1 | RELISTOR (methylnaltrexone bromide) |
| 1 | RENOVA (tretinoin cream) 0.02% for Topical Use, Pump |
| 1 | RETIN-A CREAM 45 gm 0.025% or 0.05% or 0.1% |
| 1 | RETIN-A GEL 45 gm 0.01% or 0.025% |
| 1 | RETIN-A MICRO (tretinoin) Gel Microsphere for Topical Use 0.06% or 0.08% |
| 2 | SILIQ (brodalumab) injection, for subcutaneous use, 210 mg/1.5 mL solution |
| 1 | SOLODYN (minocycline HCl) Extended Release Tablets for Oral Use 55 mg or 80 mg or 105 mg |
| 3 | SYPRINE (trientine hydrochloride) Capsules |
| 3 | TARGETIN (bexarotene) |
| 1 | TASMAR (tolcapone) Tablets |
| 1 | TETRIX CREAM |
| 1 | TRULANCE (plecanatide) 3 mg Tablets |
| 1 | UCERIS (budesonide) Rectal Foam |

| | |
|---|---|
| 1 | XIFAXAN (rifaximin) Tablets, for Oral Use, 550 mg |
| 1 | ZELAPAR (selegiline hydrochloride) Orally Disintegrating Tablets |
| 1 | ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel 60 g tube |
| 1 | ZYCLARA (imiquimod) cream 3.75%, for Topical Use 7.5 g Pump Box of 28 Packets |

Contact info-**Phone:** 833-862-8727 **Fax:** 844-705-0160

Bayer patient assistance foundation

| Eligibility | | |
|-------------|--------------------------------------|-----------------------|
| US resident | $\geq 150\%$ FPL $\leq 300\%$ FPL | Uninsured or Medicare |

Medications eligible for assistance

| |
|--|
| Adempas (riociguat) |
| Aliqopa (copanlisib) |
| ANGELIQ (drospirenone and estradiol) |
| BETASERON (interferon beta-1b) |
| BILTRICIDE (praziquantel) |
| Climara Pro (estradiol/levonorgestrel transdermal system) |
| Jivi (antihemophilic factor recombinant) |
| Kerendia (finerenone) |
| KOVALTRY (antihemophilic factor recombinant) |
| Kyleena (levonorgestrel-releasing intrauterine system) |
| Lampit (nifurtimox) |
| Menostar (estradiol transdermal system) |
| Mirena (levonorgestrel-releasing intrauterine system) |
| Natazia (estradiol valerate and estradiol valerate/dienogest) |
| Nexavar (sorafenib) |
| Nubeqa (darolutamide) |
| SAFYRAL (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets) |
| Skyla (levonorgestrel-releasing intrauterine system) |
| Stivarga (regorafenib) |
| VITRAKVI (Larotrectinib) |
| Xofigo (radium Ra 223 dichloride) |

Contact info: **Phone:** 1-866-228-7723 **Fax:** 1-866-575-6568

Boehringer Ingelheim (BI Cares Program)

Eligibility

US resident

<250% FPL

Uninsured or
Medicare

| Household size | Annual household income (\$) threshold (<u><250% FPL</u>) |
|----------------|---|
| 1 | 33,975 |
| 2 | 45,775 |
| 3 | 57,575 |
| 4 | 69,375 |
| 5 | 81,175 |

[Click for FPL for household larger than 5](#)

- Medicare patients <150% FPL will be denied until proof of [Medicare Low Income Subsidy](#) denial letter

Medications eligible for assistance

| |
|--|
| Aptivus (tipranavir) |
| Atrovent HFA (ipratropium) |
| COMBIVENT Respimat (ipratropium/albuterol) |
| GILTORIF (afatinib)^{\$} |
| Glyxambi (empaglizoin/metformin) |
| Jardiance (empagliiflozin) |
| Jentadueto & Jentadueto XR (linagliptin/metformin) |
| OFEV (nintedanib)^{\$} |
| Pradaxa (dabigatran) |
| Spiriva Handihaler or Respimat (tiotropium) |
| Stiolto Respimat (tiotropium/olodaterol) |
| Striverdi Respimat (olodaterol) |
| Synjardy & Synjardy XR (empagliiflozin/metformin) |
| Tradjenta (linagliptin) |
| Trijardy XR (empagliiflozin/linagliptin/metformin) |
| Viramune XR (nevirapine) |
| \$ Has individual application |

Contact info: **Phone:** 1-800-556-8317 **Fax:** 1-866-851-2827

Eligibility

US resident

<300% FPL for
Eliquis and Orencia

Uninsured
or Medicare

| Household size | Annual household income (\$) threshold (<u><300% FPL</u>) |
|------------------------|---|
| 1 | 40,770 |
| 2 | 54,930 |
| 3 | 69,090 |
| 4 | 83,250 |
| 5 | 97,410 |
| Each additional person | 14,160 |

Medicare patients with financial constraints can **apply if they have spent 3% of annual household** income on out-of-pocket prescription expenses

- Company may require proof of out-of-pocket expenses, which can be obtained from pharmacy
- Medications for cancer, ulcerative colitis, multiple sclerosis, and kidney transplant **can qualify with higher income thresholds** (reviewed individually)

Applications will be processed more quickly if income documentation included:

1. 1099 forms
2. Social security statement
3. Pension statements
4. Two consecutive pay stubs

Medications eligible for assistance

[ABRAXANE® \(paclitaxel protein-bound particles for injectable sUSPension \(albumin-bound\)\)](#)

[CAMZYOS \(mavacamten\)](#)

[DROXIA \(hydroxyurea\)](#)

[ELIQUIS® \(apixaban\)](#)

[EMPLICITI® \(elotuzumab\)](#)

[IDHIFA® \(Enasidenib\)](#)

[INREBIC® \(fedratinib\)](#)

[ISTODAX® \(Romidepsin\)](#)

[NULOJIX® \(belatacept\)](#)

[ONUREG® \(azactidine tablets\)](#)

[OPDIVO® \(nivolumab\)](#)

[OPDUALAG™ \(nivolumab and relatlimab – rmbw\)](#)

[ORENCIA® \(Abatacept\)](#)

[POMALYST® \(pomalidomide\)](#)

[REBLOZYL® \(luspatercept-aamt\)](#)

| |
|---|
| REVLIMID® (lenalidomide) |
| SOTYKTU (deucravacitinib) |
| SPRYCEL® (dasatinib) |
| THALOMID® (thalidomide) |
| VIDAZA® (azacitidine for injection) |
| YEROVY® (Ipilimumab) |
| ZEPOSIA® (ozanimod) |

Contact info-Phone: 1-800-736-0003 Fax: 1-800-736-1611 Fax 2: 833-967-1666
 Can upload full application online via: patientsupportnow.org Passcode: 8007361611

[GlaxoSmithKline – GSK for You](#)

Eligibility

US resident

$\leq 250\%$ FPL

Uninsured or
Medicare

| Household size | Annual household income (\$) threshold ($\leq 250\%$ FPL) |
|----------------|---|
| 1 | 33,975 |
| 2 | 45,774.96 |
| 3 | 57,575.04 |
| 4 | 69,375 |
| ≥ 5 | Add 11,859.96 |

- Does **NOT** require proof of income per application, only requires submission of application, documenting income
 - $\leq 250\%$ FPL
- No prescription drug benefit through any insurer
- Separate prescription required
- Not receiving government drug coverage (excluding Medicare)
 - Need to provide proof of \$600.00 out-of-pocket drug expenses
- Most medications sent as 90-day supply
- Refill requests to be made at least 3 weeks before existing supply will run out
- Need to recertify after 12 months

Medications eligible for assistance

| |
|---|
| ADVAIR (diskus or HFA) (Fluticasone/salmeterol) |
| ANORO ELLIPTA (Umeclidinium/vilanterol) |
| ARNUITY ELLIPTA (Fluticasone) |
| BECONASE AQ (Beclomethasone dipropionate nasal spray) |
| BENLYSTA (Belimumab) |
| BLENREP (Belantamab) |

[BOOSTRIX \(Tdap vaccine\)](#)

BREO ELLIPTA (Fluticasone/vilanterol)

EPIVIR-HBV (Lamivudine solution or tablets)

[ENGERIX-B \(Hepatitis B vaccine\)](#)

FLOVENT (diskus or HFA) (Fluticasone)

IMITREX (Sumatriptan nasal spray)

INCRUSE ELLIPTA (Umeclidinium)

JEMPERLI (Dostarlimab)

LAMICTAL (Lamotrigine chewable or orally disintegrating tablets)

LAMICTAL ODT (Lamotrigine patient titration kits)

LAMICTAL XR (Lamotrigine ER or patient titration kit)

MALARONE (Atovaquone and proguanil)

MEPRON (Atovaquone sUSPension)

NUCALA (Mepolizumab)

RELENZA (Zanamivir inhalation powder)

SEREVENT (diskus) (Salmeterol)

[SHINGRIX \(Zoster vaccine\)](#)

Contact info: **Phone:** 1-866-728-4368 **Fax:** 1-855-474-3063

[Janssen](#)

Eligibility

US resident

<300-600% FPL

Uninsured or
Medicare

| Household size | Group 1 income threshold (<u><300% FPL</u>) | Group 2 income threshold (<400% FPL) | Group 3 income threshold (<u><600% FPL</u>) |
|----------------|---|---|---|
| 1 | 40,770 | 54,360 | 81,540 |
| 2 | 54,930 | 73,240 | 109,860 |
| 3 | 69,090 | 92,120 | 138,180 |
| 4 | 83,250 | 111,000 | 166,500 |
| 5 | 97,410 | 162,350 | 194,820 |

- a. If patient elects not to have soft income check (Will NOT affect credit score) performed, must provide the following:
 - i. Copy of most recent 1040 or 1040-SR federal tax return
- b. Patients with Medicare Part D or prescription coverage **will need to spend 4% out of pocket** on prescriptions each year before being approved

Medications eligible for assistance

| Income group | Medication name |
|--------------|---|
| 3 | <u>BALVERSA® (erdafitinib) Tablets</u> |
| 3 | <u>DARZALEX® (daratumumab) Injection for intravenous infusion</u> |
| 3 | <u>DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Injection for subcutaneous use</u> |
| 1 | <u>EDURANT® (rilpivirine) Tablets</u> |
| 1 | <u>ELMIRON® (pentosan polysulfate sodium) Capsules</u> |
| 3 | <u>ERLEADA® (apalutamide) Tablets</u> |
| 3 | <u>Infliximab, For injection, for intravenous use</u> |
| 1 | <u>INTELENCE® (etravirine) Tablets</u> |
| 1 | <u>INVEGA HAFYERA™* (paliperidone palmitate) Extended-release Injectable Suspension</u> |
| 1 | <u>INVEGA SUSTENNA®* (paliperidone palmitate) Extended-release Injectable Suspension</u> |
| 1 | <u>INVEGA TRINZA®* (paliperidone palmitate) Extended-release Injectable Suspension</u> |
| 1 | <u>INVOKAMET®* (canagliflozin/metformin HCI) Tablets</u> |
| 1 | <u>INVOKAMET® XR* (canagliflozin/metformin HCI) Extended-release Tablets</u> |
| 1 | <u>INVOKANA® (canagliflozin) Tablets</u> |
| 2 | <u>OPSUMIT®* (macitentan) Tablets</u> |
| 2 | <u>PONVORY® (ponesimod) Tablets</u> |
| 1 | <u>PREZCOBIX® (darunavir 800mg/cobicistat 150mg) Tablets</u> |
| 1 | <u>PREZISTA® (darunavir) Tablets or Oral Suspension</u> |
| 3 | <u>REMICADE®* (infliximab) Intravenous Infusion</u> |
| 1 | <u>RISPERDAL CONSTA®* (risperidone) Long-acting Injection</u> |
| 3 | <u>RYBREVANT® (amivantamab-vmjw) Injection, for intravenous use</u> |
| 3 | <u>SIMPONI® (golimumab) Injection</u> |
| 3 | <u>SIMPONI ARIA®* (golimumab) Intravenous Infusion</u> |
| 1 | <u>SIRTURO®* (bedaquiline) Tablets</u> |
| 1 | <u>SPRAVATO®* (esketamine) Nasal Spray CIII, for intranasal use</u> |
| 3 | <u>STELARA® (ustekinumab) Injection, for intravenous use</u> |
| 3 | <u>STELARA® (ustekinumab) Injection, for subcutaneous use</u> |
| 1 | <u>SYMTUZA®* (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) Tablets</u> |
| 3 | <u>TECVAYLIT™ (teclistamab) Injection, for subcutaneous use</u> |
| 2 | <u>TRACLEER®* (bosentan) Tablets</u> |
| 3 | <u>TREMFYA® (guselkumab) Prefilled syringe or One-Press patient-controlled injector</u> |
| 2 | <u>UPTRAVI®† (selexipag) Tablets</u> |
| 2 | <u>VELETRI®† (epoprostenol) Injection</u> |
| 2 | <u>VENTAVIS®† (iloprost) Inhalation solution</u> |
| 1 | <u>XARELTO®* (rivaroxaban) Tablets or Oral Suspension</u> |
| 3 | <u>YONDELIS® (trabectedin) Injection for Intravenous Infusion</u> |

Contact info-Phone: 1-833-742-0791 **Fax:** 1-833-512-0497

Lilly Cares Program

Eligibility

Legal US resident

<300-500% FPL

Uninsured or Medicare

| Household size | Annual household income (\$) threshold | | |
|----------------|--|-------------------------------|-------------------------------|
| | Group 1 (<u>≤ 300% FPL</u>) | Group 2 (<u>≤ 400% FPL</u>) | Group 3 (<u>≤ 500% FPL</u>) |
| 1 | 40,770 | 54,360 | 67,950 |
| 2 | 54,930 | 73,240 | 91,550 |
| 3 | 69,090 | 92,120 | 115,150 |
| 4 | 83,250 | 111,000 | 138,750 |
| <u>≥5</u> | Call Lilly cares 1-800-545-6962 | | |

- Does not require proof of income **WITH** physician or advanced practice provider hand-written letter of financial situation
- Patient will need to coordinate shipment by calling LabCorp Specialty Pharmacy 866-842-2147

Medications eligible for assistance

| Insurance Group | Medication name | Package insert | Patient education |
|-----------------|--|---|-------------------------------------|
| 3 | Alimta® (pemetrexed for injection) | Prescribing Information | Patient Information |
| 2 | Baqsimi® (glucagon) nasal powder | Prescribing Information | Patient Information |
| 2 | Basaglar® (insulin glargine injection) | Prescribing Information | Patient Information |
| 2 | Cialis® (tadalafil) tablets | Prescribing Information | Patient Information |
| 1 | Cymbalta® (duloxetine delayed-release capsules) | Prescribing Information | Medication Guide |
| 3 | Cyramza® (ramucirumab) injection | Prescribing Information | |
| 2 | Emgality® (galcanezumab-gnlm) injection | Prescribing Information | Patient Information |
| 3 | Erbitux® (cetuximab) injection | Prescribing Information | |

| | | | |
|---|--|---|---|
| 1 | Evista® (raloxifene hydrochloride) Tablet | Prescribing Information | Medication Guide |
| 1 | Forteo® (teriparatide injection) | Prescribing Information | Medication Guide |
| 2 | Glucagon™ (glucagon for injection) | Prescribing Information | Patient Information |
| 2 | Humalog® U-100 (insulin lispro injection) | Prescribing Information | Patient Information |
| 2 | Humalog® U-200 (insulin lispro injection) | Prescribing Information | Patient Information |
| 2 | Humalog® Mix50/50™ (insulin lispro protamine and insulin lispro injectable sUSPension) | Prescribing Information | Patient Information |
| 2 | Humalog® Mix75/25™ (insulin lispro protamine and insulin lispro injectable sUSPension) | Prescribing Information | Patient Information |
| 3 | Humatrope® (somatropin) for injection | Prescribing Information | Patient Information: Cartridge Patient Information: Vial |
| 2 | Humulin® 70/30 (human insulin isophane sUSPension and human insulin injection) | Prescribing Information | Patient Information |
| 2 | Humulin® N (isophane insulin human sUSPension) | Prescribing Information | Patient Information |
| 2 | Humulin® R (insulin human injection) | Prescribing Information | Patient Information |
| 2 | Humulin® R U-500 (insulin human injection) | Prescribing Information | Patient Information |
| 2 | Lyumjev™ (insulin lispro-aabc) injection | Prescribing Information | Patient Information |
| 3 | Olumiant® (baricitinib) tablets | Prescribing Information | Medication Guide |
| 3 | Portrazza® (necitumumab) injection | Prescribing Information | |
| 1 | Prozac® (fluoxetine capsules) | Prescribing Information | Medication Guide |
| 3 | Retevmo™ (selpercatinib) capsules | Prescribing Information | Patient Information |
| 2 | Reyvow® (lasmiditan) tablets C-V | Prescribing Information | Medication Guide |
| 1 | Strattera® (atomoxetine) capsules | Prescribing Information | Medication Guide |
| 1 | Symbax® (olanzapine and fluoxetine) capsules | Prescribing Information | Medication Guide |
| 3 | Taltz® (ixekizumab) injection | Prescribing Information | Medication Guide |

| | | | |
|---|---|---|-------------------------------------|
| 2 | Trulicity® (dulaglutide) injection | Prescribing Information | Medication Guide |
| 3 | Verzenio® (abemaciclib) tablets | Prescribing Information | Patient Information |
| 1 | Zyprexa® (olanzapine) Tablet | Prescribing Information | Medication Guide |
| 1 | Zyprexa® Zydis® (olanzapine) Tablet | Prescribing Information | Medication Guide |

Contact info-Phone: 1-800-545-6962 Fax: 1-844-431-6650

[Merck and Co – Merck Helps: patient assistance program](#)

Eligibility

US
resident

>19 years
old if
applying for
vaccine

<400% FPL

Uninsured/
Medicare

| Household size | Annual household income (\$) threshold (≤400% FPL) |
|----------------|---|
| 1 | 54,360 |
| 2 | 73,240 |
| 3 | 92,120 |
| 4 | 111,000 |
| 5 | 129,880 |
| ≥5 | Add 4,720 for each additional person |

1. Does **NOT** require proof of income
2. Applications must be MAILED to: PO box 690, Horsham, PA 19044-9979
 - a. Once application submitted, Medicare patients will receive attestation that needs signed and returned to program

Medications eligible for assistance

[BELSOMRA®](#) (suvorexant) C-IV

[CANCIDAS®](#) (caspofungin acetate) for Injection

[DELSTRIGO™](#) (doravirine, lamivudine, and tenofovir disoproxil fumarate) tablets, for oral use

[DIFICID®](#) (fidaxomicin) tablets

[DIFICID®](#) (fidaxomicin) for oral sUSPension 40 mg/mL

[EMEND®](#) (aprepitant) for Oral SUSPension 125 mg

[EMEND®](#) (aprepitant) 80 mg, 125 mg capsules

| |
|--|
| EMEND® (fosaprepitant dimeglumine) for Injection 150 mg |
| GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) |
| ISENTRESS® (raltegravir) 400 mg film-coated and 25 mg and 100 mg chewable Tablets |
| ISENTRESS® HD (raltegravir) 600 mg Tablets |
| JANUMET® (sitagliptin and metformin HCI) Tablets |
| JANUMET® XR (sitagliptin and metformin HCI extended-release) Tablets |
| JANUVIA® (sitagliptin) Tablets |
| KEYTRUDA® (pembrolizumab) Injection [liquid formulation] 100 mg |
| M-M-R® II (Measles, Mumps, and Rubella Virus Vaccine Live) |
| NOXAFIL® (posaconazole) oral sUSPension, 40 mg/mL |
| PIFELTRO™ (doravirine) tablets, for oral use |
| PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent) |
| PREVYMIS™ (letermovir) 240 mg Tablets |
| RECARBRIOTM (imipenem, cilastatin, and rebetolam) for injection, for intravenous use |
| RECOMBIVAX HB® [Hepatitis B Vaccine (Recombinant)] |
| STROMECTOL® (ivermectin) Tablets |
| TRUSOPT® (dorzolamide hydrochloride ophthalmic solution) 2% |
| VAQTA® (Hepatitis A Vaccine, Inactivated) |
| VARIVAX® (Varicella Virus Vaccine Live) |
| VAXNEUVANCE™ (Pneumococcal 15-valent conjugate vaccine) |
| VERQUVOTM (vericiguat) 2.5 mg, 5 mg, 10 mg tablets |
| WELIREG™ (belzutifan) 40 mg Tablets |
| ZEPATIER® (elbasvir and grazoprevir) |
| ZERBAXA™ (ceftolozane and tazobactam) for Injection for Intravenous Use |
| ZINPLAVA™ (bezlotoxumab) Injection 25 mg/ml |
| ZOLINZA® (vorinostat) 100 mg Capsules |

Contact info-Phone: 1-800-727-5400

Program details

- Single application can include up to 3 Merck products
- Each prescription cannot exceed a 90-day supply at a time with a maximum of 3 refills
- New application needed every 12 months

[MyPrudent Patient Assistance Program](#)

| Eligibility | | |
|-------------|--|-----------------------------|
| US resident | $\leq 300\% \text{ FPL}$ $\text{BUT } \geq 135\% \text{ FPL}$ | Uninsured or Medicare |

- Commercially insured patients copay card

| Household size | Annual household income (\$) threshold (<u><300% FPL</u>) |
|----------------|---|
| 1 | 40,770 |
| 2 | 54,930 |
| 3 | 69,090 |
| 4 | 83,250 |
| <u>≥5</u> | Contact myPraluent program at 1-844-772-5836 |

- Must be above 135% FPL, as patient would then qualify for LIS but below 300% FPL
- Proof of income may be asked for, which needs provided within 30 days of request
- [Can apply online](#)

Medication eligible for assistance

Praluent (alirocumab)

Contact info-**Phone:** 1-844-772-5836 **Fax:** 1-844-855-7278

Mylan pharmaceuticals now Viatris

Eligibility

US resident

≤ 400-500% FPL

Uninsured or
Medicare

| Household size | Annual household income (\$) threshold | |
|----------------|--|--|
| | Group 1 & 2 medications <u><400% FPL</u> | Fulphila & Ogviri (<u><500% FPL</u>) |
| 1 | 54,360 | 67,950 |
| 2 | 73,240 | 91,550 |
| 3 | 92,120 | 115,150 |
| 4 | 111,000 | 138,750 |
| 5 | 129,880 | 162,350 |
| <u>≥5</u> | Add 23,600 for each additional person in household | |

- a. Verification Documents:
 - i. 1040
 - ii. 1040ez
 - iii. W2
 - iv. 4506-T
 - v. SSI Statement
 - vi. Disability Statement
 - vii. **Statement from Provider, Nurse, or Patient Advocate**
 - viii. Certified Notarized Statement from the Applicant

Medications eligible for assistance

| Insurance Group | Medication name |
|-----------------|--|
| 1 | Arixtra (fondaparinux) |
| 2 | Caduet (amlodipine/atorvastatin) |
| 1 | Cimduo (lamivudine/tenofovir disoproxil fumarate) tablet |
| 1 | Clozapine |
| 1 | Cortifoam (hydrocortisone 10%) rectal foam |
| 1 | Cystagon (cysteamine) capsules |
| 1 | Denavir (penciclovir) cream 1% |
| 1 | Depen (penicillamine) tablets |
| 2 | Detrol LA (tolterodine) |
| 1 | Dipentum (olsalazine) capsule |
| 1 | Dymista (azelastine/fluticasone) nasal spray |
| 1 | Elestrin (estradiol gel) 0.06% |
| 1 | Emsam transdermal system |
| 2 | EpiPen & EpiPen Jr (epinephrine) injection |
| 1 | Erygel (erythromycin) topical gel 2% |
| 1 | Evoclin (clindamycin) foam 1% |
| 1 | Felbatol (felbamate) |
| 2 | Fulphila (pegfilgastrim-jmdb)* |
| 1 | Gastrocrom (cromolyn) oral concentrate |
| 2 | Glatiramer Acetate |
| 1 | Impekllo (clobetasol) lotion |
| 2 | Inspra (eplerenone) |
| 1 | Luxiq (betamethasonevalerate) foam |
| 1 | Miacalcin injection (calcitonin) |
| 1 | Muse (alprostadil) urethral |
| 2 | Ogivri * (trastuzumab-dkst) |
| 1 | Olux (clobetasol) foam 0.05% |
| 1 | Olux-E (clobetasol) foam 0.05% |
| 1 | Performist (formoterol fumarate) inhalation solution |
| 1 | Pretomanid tablet |
| 1 | Proctofoam HC (hydrocortisone acetate 1% & pramoxine 1%) |
| 2 | Relpax (eletriptan) |
| 1 | Rowasa (mesalamine) rectal sUSPension |
| 1 | Semglee (insulin glargine) |

[RETURN TO TOP](#)

| | |
|---|--|
| 1 | SF Rowasa (mesalamine) rectal sUSPension |
| 2 | Tobi (tobramycin) ampules or podhalers |
| 1 | Wixela (fluticasone/salmeterol) |
| 1 | Xulane (norelgestromin and ethinyl estradiol transdermal system) |
| 1 | Yupelri (revefenacin) |

*FPL threshold 500%

Contact info-Phone: 888-417-5780 Fax: 877-427-7290

[Nestle Health Science Patient assistance program](#)

Eligibility

US resident

\leq 400 FPL

Uninsured

| Household size | Annual household income (\$) threshold (\leq 400% FPL) |
|----------------|--|
| 1 | 54,360 |
| 2 | 73,240 |
| 3 | 92,120 |
| 4 | 111,000 |
| 5 | 129,880 |
| ≥ 5 | Add 4,720 for each additional person |

- a. Proof of income required: W-2, federal tax return, current pay stubs, monthly healthcare benefits statement, social security award letter or bank statement showing monthly direct deposit
- b. If self-employed must attach Federal tax income statement
- c. **If no income, need a letter from provider or social worker on healthcare letterhead**

Medication eligible for assistance

Viokace (pancrelipase) tablets

Zenpep (pancrelipase) delayed release capsule

Contact info-Phone: 1-855-210-6228 Fax: 1-877-867-1831

Novartis Patient Assistance Foundation

Eligibility

US resident

<400% FPL

Uninsured
or Medicare

| Household size | Annual household income (\$) threshold |
|----------------|--|
| 1 | 54,360 |
| 2 | 73,240 |
| 3 | 92,120 |
| 4 | 111,000 |
| ≥5 | Add 18,880 per additional person |

- a. Needs to check box to allow for income verification which will NOT affect credit score
- b. OR submit one of the following:
 - i. Most recent federal tax return
 - ii. W-2 form
 - iii. Three months of paycheck stubs
 - iv. Social security statement (1099)
- 2. Limited or no private or public prescription coverage
- 3. **Separate prescription required**
- 4. Patients **MUST** call for refills, **NOT** automatically refilled
- 5. Separate prescription must be faxed in by provider to 1-855-817-2711

Medications eligible for assistance

Adakveo® (crizanlizumab-tmca)

Afinitor® (everolimus)

Afinitor Disperz® (everolimus sUSPension)

Alomide® (lodoxamide tromethamine solution)

Beovu® (brolucizumab-dbll) Injection

Betoptic S® (betaxolol hydrochloride sUSPension)

Coartem® (artemether and lumefantrine)

Cosentyx® (secukinumab)

Entresto™ (sacubitril/valsartan)

Extavia® (interferon beta-1b)

Ferumoxytol injection

Fulvestrant injection, for intramuscular use

Gilenya® (fingolimod)

Hycamtin® (topotecan) Capsules

Hycamtin® (topotecan hydrochloride) For Injection

Ilaris® (canakinumab)

Ilevro® (nepafenac sUSPension)

| |
|---|
| Jadenu® (deferasirox) |
| Jadenu® Sprinkle (deferasirox) granules |
| Kesimpta® (ofatumumab) |
| Kisqali® (ribociclib) |
| Kisqali® Femara® Co-Pack (ribociclib and letrozole) tablets |
| Leqvio® (Inclisiran) |
| Lutathera® (lutetium Lu 177 dotataate) |
| Levooleucovorin Injection |
| Maxidex® (dexamethasone sUSPension) |
| Mayzent® (Siponimod) |
| Mekinist® (trametinib) |
| Nevanac® (nepafenac sUSPension) |
| Omnitrope® Somatropin (rDNA origin) |
| Piqray® (alpelisib) |
| Pluvicto® (177Lu-PSMA-617) |
| Promacta® (eltrombopag) |
| RYDAPT® (midostaurin) |
| SANDOSTATIN LAR® DEPOT (octreotide acetate) |
| Scemblix® (asciminib) Tablets |
| Tabrecta™ (capmatinib) |
| Tafinlar® (dabrafenib) |
| Tasigna® (nilotinib) |
| Tobradex® (ophthalmic ointment) |
| Triesence® (triamcinolone acetonide injectable sUSPension) |
| Tykerb® (lapatinib) |
| Vijoice® (alpelisib) |
| Votrient® (pazopanib) |
| Xiidra® (lifitegrast ophthalmic solution) |
| Zarxio™ (filgrastim-sndz) |
| Ziextenzo® (pegfilgrastim-bmez) |
| ZYKADIA® (ceritinib) |

Contact info-**Phone:** 1-800-277-2254 **Fax:** 1-855-817-2711

Novo Nordisk (up to 10 days for processing)

| Eligibility | | |
|-------------|-----------------|-----------------------|
| US citizen | \leq 400% FPL | Uninsured or Medicare |

| Household size | Annual household income (\$) threshold (≤400% FPL) |
|----------------|---|
| 1 | 54,360 |
| 2 | 73,240 |
| 3 | 92,120 |
| 4 | 111,000 |
| 5 | 129,880 |
| ≥5 | Add 4,720 for each additional person |

- Do **NOT** need proof of income if financial constraint is secondary to COVID-19
- Otherwise need:
 - Two most current paycheck stubs or earning statements for all working members of your household
 - Last year's federal Individual Income Tax Return (1040)
 - Social Security income, pension, and other income statements
 - W-2 or 1099 forms
 - Unemployment benefit statements
- Not enrolled or does not qualify for federal, state, or government program

Medications are sent to primary care office if approved

Medications eligible for assistance

Fiasp Flextouch (insulin aspart)*

Glucagon Hypokit

Levemir (insulin detemir) Flextouch*

Novolin N vial (insulin NPH)

Novolin 70/30 (insulin NPH and insulin R mix) vial

Novolin R vial (insulin regular)

Novolog (insulin aspart) FlexPen*

Novolog mix 70/30 (insulin aspart protamine and insulin aspart) FlexPen*

Ozempic (semaglutide) injection*

Rybelsus (semalglutide) tablets

Tresiba (insulin degludec) FlexTouch*

Victoza (liraglutide) pen*

Xultophy (insulin degludec & liraglutide) pen*

*Request Novo Nordisk disposable needles on prescription/application or they will not be sent

Contact info- **Phone:** 1-866-310-7549 **Fax:** 1-866-441-4190

Otsuka Patient Assistance Foundation

Eligibility

US citizen

$\leq 300\% - 700$ FPL

Uninsured

| Household size | Annual household income (\$) threshold | |
|----------------|---|--------------------------|
| | All other medications ($\leq 300\%$ FPL) | Jynarque ($<700\%$ FPL) |
| 1 | 40,770 | 109,860 |
| 2 | 54,930 | 138,180 |
| 3 | 69,090 | 166,500 |
| 4 | 83,250 | Add 28,320 |
| ≥ 5 | Call Otsuka 1-855-727-6274 | |

- a. Must show proof of residency by submitting **ONE** of the following:
 - i. Social Security number
 - ii. State driver's license
 - iii. US birth certificate
 - iv. US passport
 - v. Foreign passport with US visa
 - vi. I-94 form with photograph
 - vii. US military ID
 - viii. US certificate of naturalization or citizenship
- b. Must provide **ONE** of the following:
 - i. Federal Income Tax Return (1040, etc)
 - ii. Social Security award letter
 - iii. W-2 from previous tax year
 - iv. Disability income information
 - v. 1099-MISC form
 - vi. Unemployment benefits letter
 - vii. 2 most recent paystubs
 - viii. Letter from employer on company letterhead
- c. Application mentions that income verification will be done electronically (will NOT affect credit score) if financial documentation cannot be provided

Medications eligible for assistance

[Abilify Maintena \(aripiprazole\) for extended release injectable sUSPension](#)

[Jynarque \(tolvaptan\) tablets](#)

[Rexulti \(Brexpiprazole\) tablets](#)

Pfizer RxPathways patient assistance program (2-3 weeks for processing)

Eligibility

US resident

\leq 400% FPL

Uninsured

| Household size | Annual household income (\$) threshold | |
|----------------|--|---------|
| | Non-B medications \leq 400% FPL | Group B |
| 1 | 54,360 | 49,960 |
| 2 | 73,240 | 67,640 |
| 3 | 92,120 | 85,320 |
| 4 | 111,000 | 103,00 |
| 5 | 129,880 | 120,680 |
| \geq 5 | Call Pfizer program 1-866-706-2400 | |

- Requires photocopy of **one** of the following for income verification:
 1. Pages one and two of previous year federal tax return (1010 or 1040 EZ)
 2. Wage and tax statements (W-2 forms)
 3. Two recent paycheck stubs
 4. Social security, pension, or railroad retirement statements (SSA-1099 or similar)
 5. Statements of interest, dividends, or other income (1099-INT, 1099-DIV, or similar)
- Annual income cutoff is \leq 400% FPL
- **Patient and provider need to register online or call 1-866-706-2400 and application will be faxed**

See link [page 2](#) for additional medications that qualify for savings for uninsured patients through local pharmacy, regardless of income

Medications eligible for assistance

| Insurance Group | Medication name |
|-------------------|--|
| B | VFEND® (voriconazole) |
| B | Revatio (sildenafil) |
| B | RAPAMUNE® (sirolimus) |
| Non-B medications | AROMASIN® (exemestane) tablets |
| | ARTHROTEC® (diclofenac sodium/misoprostol) tablets |

| |
|---|
| BeneFIX® Coagulation Factor IX (Recombinant) |
| BESPONSA™ (inotuzumab ozogamicin, for injection, for intravenous use) |
| BOSULIF® (bosutinib) tablets |
| CADUET® (amlodipine besylate/atorvastatin calcium) tablets |
| CAMPTOSAR® (irinotecan hydrochloride) injection |
| CAVERJECT® (alprostadil) injection |
| CAVERJECT® Impulse® (alprostadil) injection |
| CELEBREX® (celecoxib) capsules |
| CELONTIN® (methsuximide) capsules, USP |
| CHANTIX® (varenicline) tablets |
| CIBINQO™ (abrocitinib) tablets |
| DAURISMO™ (glasdegib) tablets |
| DEPO-PROVERA® (medroxyprogesterone acetate injectable sUSPension) |
| DEPO®-ESTRADIOL (estradiol cypionate) injection, USP |
| DETROL® (tolterodine tartrate) tablets |
| DETROL® LA (tolterodine tartrate) extended-release capsules |
| DILANTIN® (extended phenytoin sodium) capsules |
| DUAVEE™ (conjugated estrogens/bazedoxifene) tablets |
| ELLENCE® (epirubicin hydrochloride injection) |
| EMCYT® (estramustine phosphate sodium) capsules |
| ESTRING® (estradiol vaginal ring) |
| FELDENE® (piroxicam) capsules |
| FRAGMIN® (dalteparin sodium) injection |
| GENOTROPIN® (somatropin) for injection |
| HEPARIN Sodium Injection, USP |
| IBRANCE® (palbociclib) capsules |
| IDAMYCIN PFS® (idarubicin hydrochloride) injection |
| INFLECTRA® (infliximab-dyyb) for injection |
| INLYTA® (axitinib) tablets |
| INSPRA® (eplerenone) tablets |
| LEVOXYL® (levothyroxine sodium) tablets |
| LINCOCIN® (lincomycin) injection, USP |
| LORBRENA® (lorlatinib) tablets |
| MENEST® (esterified estrogens) tablets, USP |
| MYCOBUTIN® (rifabutin) capsules, USP |
| MYLOTARG™ (gemtuzumab ozogamicin) for injection |

| | |
|--|---|
| | NICOTROL® (nicotine) |
| | NIVESTYM® (filgrastim-aafi) injection |
| | NORPACE® (disopyramide phosphate) |
| | PREMARIN® (conjugated estrogens) tablets, USP (conjugated estrogens tablets) |
| | PREMARIN® (conjugated estrogens) Vaginal Cream (conjugated estrogens) Vaginal Cream |
| | PREMPRO® (conjugated estrogens/medroxyprogesterone acetate) tablets |
| | PREMPHASE® (conjugated estrogens plus medroxyprogesterone acetate) tablets |
| | PREVNAR 13® Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein] |
| | PRISTIQ® (desvenlafaxine) extended-release tablets |
| | RELPAX® (eletriptan hydrobromide) tablets |
| | RETACRIT® (epoetin alfa-epbx) injection |
| | SKELAXIN® (metaxalone) tablets |
| | SOMAVERT® (pegvisomant) for injection |
| | SUTENT® (sunitinib malate) capsules |
| | SYNAREL® (nafarelin acetate) nasal solution |
| | TALZENNA® (talazoparib) capsules |
| | TIKOSYN® (dofetilide) capsules |
| | TORISEL® (temsirolimus) injection |
| | TOVIAZ® (fesoterodine fumarate) extended-release tablets |
| | TRECATOR® (ethionamide) tablets |
| | TRUMENBA® (Meningococcal Group B Vaccine) |
| | TYGACIL® (tigecycline) for injection |
| | VIZIMPRO® (dacomitinib) tablets |
| | VYNDAQEL® (tafamidis meglumine) capsules |
| | XALKORI® (crizotinib) capsules |
| | XANAX® CIV (alprazolam) tablets |
| | XELJANZ® (tofacitinib) tablets |
| | XELJANZ® (tofacitinib) oral solution |
| | XELJANZ® XR (tofacitinib) extended-release tablets |
| | XYNTHA® Antihemophilic Factor (Recombinant) |
| | ZARONTIN® (ethosuximide) ZYVOX® (linezolid) |
| | ZYVOX® (linezolid) |

Contact info-Phone: 1-866-706-2400 Fax: 1-866-470-1748

Eligibility

US resident

\leq 500% FPL

Uninsured or
insurance not
covering
medication

| Household size | Annual household income (\$) threshold (\leq 500% FPL) |
|----------------|--|
| 1 | 67,950 |
| 2 | 91,550 |
| 3 | 115,150 |
| 4 | 138,750 |
| \geq 5 | Click for FPL for household larger than 5 or add 23,600 per each additional person |

[Patient assistance \(free medication\)](#) for uninsured patients

- a. \leq 500% FPL (must opt in to electronic income verification **OR** provide 1040 form page 1, W-2 or other income verification)

Medications available for assistance

| |
|-------------------------|
| AROMASIN (exemestane) |
| BOSULIF (bosutinib) |
| BRAFTOVI (encorafenib) |
| DAURISMO (glasdegib) |
| EMCYT (estramustine) |
| IBRANCE (Palbociclib) |
| INLYTA (axitinib) |
| LORBRENA (lorlatinib) |
| MEKTOVI (bibimetinib) |
| SUTENT (sunitinib) |
| TALZENNA (talazoparib) |
| VIZIMPRO (dacaomitinib) |
| XALKORI (crizotinib) |
| BESPONSA (inotuzumab) |
| CAMPTOSAR (irinotecan) |
| ELLENCE (epirubicin) |
| IDAMYCIN (idarubicin) |

| |
|-------------------------------|
| MYLOTARG (gemtuzumab) |
| TORISEL (temsirolimus) |
| NIVESTYM (filgrastim-aafi) |
| NYVEPRIA (pegfilgrastim-apgf) |
| RETACRIT (epoetin alfa-epbx) |
| RUXIENCE (rituximab-pvvr) |
| TRAZIMERA (trastuzumab-qyyp) |
| ZIRABEV (bevacizumab-bvzr) |

Contact info-Phone: 1-877-744-5675 Fax: 1-877-736-6506

- [Commercially insured patients copay card](#)

Radius Assist

Eligibility

Legal US resident

\leq 300% FPL

Uninsured or Medicare

| Household size | Annual household income (\$) threshold (\leq 300% FPL) |
|----------------|--|
| 1 | 40,770 |
| 2 | 54,930 |
| 3 | 69,090 |
| 4 | 83,250 |
| \geq 5 | Contact Radius program at 1-866-896-5674 |

1. If proof of income not available, can provide social security number for income verification
2. Medicare patients that are NOT:
 - a. Enrolled in Medicaid, Veterans benefits, Indian health services
 - b. Eligible for full low-income subsidy (LIS) from social security administration

Medication eligible for assistance

TYMLOS (abaloparatide) injection

Contact info-Phone: 1-866-896-5674 Fax: 1-800-910-4610

Roche through Genentech

Program eligibility

1. Uninsured making <\$150,000
2. Insured patients as follows:

| Household size | Annual household income (\$) threshold |
|----------------|--|
| 1 | <75,000 |
| 2 | <100,000 |
| 3 | <125,00 |
| 4 | <150,000 |
| <u>≥5</u> | Add 25,000 for each additional person |

- Does **NOT** require proof of income
 - Program may ask for a copy of IRS 1040 form or other proof of income however

Documents that need filled out for every medication:

1. [Patient consent form](#)
2. [Prescriber form](#)

Medications available for assistance

[Actemra \(tocilizumab\)¹](#)

Copay card: <https://www.racopay.com/hcp/login>

Activase (alteplase)

Alcensa (alectinib)

Avastin (bevacizumab)

Cathflo Activase (alteplase)

Cotellic (cobimetinib)

Enspryng (satralizumab-mwge)

Erivedge (vismodegib)

Esbriet (pirfenidone)

Evrysdi (risdiplam)

Gavreto (pralsetinib)

Gazyva (Obinutuzumab)

Hemlibra (emicizumab-kxwh)

Herceptin (trastuzumab)

Herceptin Hylecta (trastuzumab and hyaluronidase-oysk)

Kadcyla (ado-trastuzumab emtansine)

Lucentis (ranibizumab injection)

Ocrevus (orelizumab)

Pegasys (peginterferon alfa-2a)

Perjeta (pertuzumab)

Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf)

Polivy (polatuzumab vedotin-ppiq)

Pulmozyme (dornade alfa) inhalation solution

[Rituxan \(rituximab\) for rheumatoid arthritis¹](#)

[Rituxan \(rituximab\) for oncology](#)

[Rituxan \(rituximab\) for granulomatosis with polyangiitis \(GPA\), microscopic polyangiitis \(MPA\) or pemphigus vulgaris \(PV\)](#)

[Rituxan hycela \(rituximab/hyaluronidase human\)](#)

[Rozlytrek \(entrectinib\)](#)

[Susvimo \(ranibizumab\)](#)

[Tecentriq \(atezolizumab\)](#)

[TNKase \(Tenecteplase\)](#)

[Vabysmo \(faricimab-svoa\)](#)

[Venclexta \(venetoclax tablets\)](#)

[Xeloda \(capecitabine\)](#)

[Xolair \(omalizumab\)](#)

[Zelboraf \(vemurafenib\)](#)

1. \$5.00 copay, up to \$15,000 in assistance annually for drug costs and up to \$2,000 in infusion assistance

[Additional programs for Cellcept, Evrysdi, Valcyte, Fuzeon, Nutropin available](#)*

Contact info-**Phone:**(888)-941-3331 **Fax:** (833)-999-4363

Sanofi

Sanofi patient connection program (5-7 days medication sent directly to primary care provider office)

Eligibility

Legal US
resident

\leq 400% FPL

Uninsured or
Medicare

| Household size | Annual household income (\$) threshold (\leq 400% FPL) |
|----------------|--|
| 1 | 54,360 |
| 2 | 73,240 |
| 3 | 92,120 |
| 4 | 111,000 |
| 5 | 129,880 |

- a. If eligible for Medicaid, will need to show proof of Medicaid denial
- b. Does **NOT** require income documents
 - i. Patient signs authorization for soft credit check to verify income (will NOT impact credit score)
2. For vaccine eligibility, must be >19 years of age
 - Medications are typically shipped as 90 day supply

Medications eligible for assistance

| |
|--|
| Adacel® (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed) |
| Admelog® (insulin lispro injection) 100 Units/mL |
| Apidra® (insulin glulisine injection) 100 Units/mL |
| Imogam® Rabies-HT Immune Globulin, [Human] USP, Heat Treated |
| Imovax® Rabies Vaccine [Human Diploid Cell] |
| Lantus® (insulin glargine injection) 100 Units/mL |
| Lovenox® (enoxaparin sodium injection) ¹ |
| MenQuadfi® (Meningococcal [Groups A, C, Y, W] Conjugate Vaccine) |
| Mozobil® (plerixafor injection) ¹ |
| Multaq® (dronedarone) Tablets |
| Pentacel® Diphteria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine |
| Priftin® (rifapentine) Tablets |
| Soliqua® 100/33 (insulin glargine & lixisenatide) injection 100 Units/mL and 33 mcg/mL |
| Tenivac® (tetanus and diphtheria toxoids adsorbed |
| Thymoglobulin® [Anti-Thymocyte Globulin (Rabbit)] ¹ |
| Toujeo® (insulin glargine injection) 300 Units/mL (1.5 mL or 3.0 mL pens) ² |
| 1. if applying for Drug Replacement (Lovenox®, Mozobil®, and Thymoglobulin®), a copy of the claim, denial, flow sheet(s) and drug dispensing log (with patient name, date of service, product NDC/Lot #, total dosage) must be submitted |
| 2. Regular SoloStar® is packaged as 3 pens per pack 450 units/pen; dials up to 80 units per single injection. Max SoloStar® is packaged as 2 pens per pack 900 units/pen; dials up to 160 units per single injection; Max pen dials in 2-unit increments |

Sanofi Temporary Access Program

- Once an application for the Sanofi Patient Assistance Program has been submitted, patient can qualify for a 30-day immediate access voucher ID to cover the first fill while the application processes
 - Eligible medications:
 - Admelog
 - Apidra
 - Lantus
 - Multaq
 - Soliqua 100/33
 - Toujeo
 - After application is submitted, call Sanofi Patient Connection at **888-847-4877** and inform representative that patient is interested in Sanofi Temporary Access Program
 - Patient or representative of patient will need to answer a few short questions
 - Patient will be provided a voucher ID and pharmacy numbers to take to pharmacy
 - Voucher covers up to 2 injectable brands (150mL max) and/or up to one 60 tablet package of Multaq (dronedarone) 400mg tablets
- ***One voucher for temporary access per lifetime, cannot be used for readmissions***

Sanofi copay cards for commercial insurance

- [Apidra](#)
- [Lantus](#)
- [Toujeo](#)

Sanofi Valyou program without insurance regardless of income

Eligible medications

Insulin

- [Admelog](#)
- [Apidra](#)
- Toujeo
- Lantus

Patients that do **NOT** qualify

- Medicare
- Medicaid
- VA
- DOD
- TRICARE
- Commercial or private insurance

Program details

- Patients must fill all Sanofi products at the same time for maximum savings (i.e. Fill Lantus and Admelog at the same time)
- Patients pay \$99 for up to 10 vials or packs of SoloStar PENS per fill or up to 5 packs of Max SoloStart pens per fill
 - Valid for one fill per month

Contact info-**Phone:** 1-888-847-4877 **Fax:** 1-888-847-1797

Sunovion Prescription Assistance Program

Eligibility

US resident

\leq 300% FPL

Uninsured or
Medicare

| Household size | Annual household income (\$) threshold (<u>$\leq$300% FPL</u>) |
|----------------|--|
| 1 | 40,770 |
| 2 | 54,930 |
| 3 | 69,090 |
| 4 | 83,250 |

a. **Requires** proof of income with one of the following:

- i. Current paycheck stubs, proof of Social Security Income, 1099 or W-2 forms for all members of household
- ii. Federal Income Tax Return (IRS Form 1040 or 1040EZ) for prior tax year

[RETURN TO TOP](#)

Medications eligible for assistance

[Aptiom® \(eslicarbazepine acetate\)](#)

[Kynmobi™ \(apomorphine hydrochloride\)](#)

[Latuda \(lurasidone\)](#)

Contact info-**Phone:** 877-850-0819 **Fax:** 877-850-0821

TAKEDA: Help at Hand

Eligibility

US resident

≤ 500% FPL

Any insurance status

| Household size | Annual household income (\$) threshold (≤500% FPL) |
|----------------|--|
| 1 | 67,950 |
| 2 | 91,550 |
| 3 | 115,150 |
| 4 | 138,750 |
| ≥5 | Click for FPL for household larger than 5 or add 23,600 per each additional person |

Medications eligible for assistance

[Amitiza \(lubiprostone\)](#)

[Carbatrol \(carbamazepine extended-release\) capsules](#)

[Colcrys \(colchicine\) tablets](#)

[Desilant \(dexlansoprazole\) DR capsules](#)

[Fosrenol \(lanthanum carbonate\)](#)

[Intuniv \(guanfacine\) ER tablets](#)

[Kazano \(alogliptin/metformin\) tablets](#)

[Lialda \(mesalamine\) DR tablets](#)

[Motegrity \(prucalopride\) tablets](#)

[Mydayis \(amphetamine\) ER capsules](#)

[Nesina \(alogliptin\) tablets](#)

Oseni (alogliptin/pioglitazone) tablets

Pentasa (mesalamine) ER capsules

Prevacid (lansoprazole) ODT tablets

Rozerem (ramelteon) tablets

Trintellix (vortioxetine tablets)

Vyvanse (lisdexamfetamine) capsules and tablets

Contact info-**Phone:** 1-800-830-9159 **Fax:** 1-800-497-0928

TEVA Cares Foundation

Eligibility

US resident

≤ 300-500% FPL

Uninsured or
Medicare A/B
ONLY

| Household size | Annual household income (\$) threshold | |
|----------------|--|--|
| | Non-oncology medications <u>≤300% FPL</u> | Oncology medications <u>≤500% FPL</u> |
| 1 | 40,770 | 67,950 |
| 2 | 54,930 | 91,550 |
| 3 | 69,090 | 115,150 |
| 4 | 83,250 | 138,750 |
| 5 | 97,410 | 162,350 |
| <u>≥5</u> | Click for FPL thresholds | |

- a. Does **NOT** require proof if patient consents to electronic income verification (does NOT affect credit score)
- b. Otherwise will need to submit one or more of the following for all members of household
 - i. A copy of your most recently filed Federal Income Tax Return or Forms (1040, 1040EZ, 1099, 1099-DIV or 1099-INT)
 - ii. Social Security Income Yearly Benefits Statement (SSA, 1099-R, or Awards Letter)
 - iii. IRS Transcript
 - iv. Pay stubs
 - v. Unemployment Letter or Worker's Compensation
 - vi. Veterans Benefits
 - vii. Alimony/Child Support
 - viii. Rental Income
 - ix. Employer Letter on Company Letterhead

- x. Zero Income Letter from social worker, clergy, provider, or patient/family explaining how patient is surviving with no income

Medications eligible for assistance

[BENDEKA \(bendamustine\)](#)

[Clozapine](#)

[Cyclosporine capsules modified](#)

[Cyclosporine oral solution modified](#)

[GABITRIL \(tigabine hydrochloride\) tablets](#)

[GALZIN \(zinc acetate\) capsules](#)

[GRANIX \(tbo-filgrastim\) injection](#)

[HERZUMA \(trastuzumab-pkrb\) injection](#)

[NUVIGIL \(armodafinil\) tablets \[C-IV\]](#)

[ProAir RespiClick \(albuterol sulfate\) inhalation aerosol](#)

[ProAir HFA \(albuterol sulfate\) inhalation aerosol](#)

[Proglycem \(diazoxide\) oral sUSPension](#)

[QNASL \(beclomethasone\) nasal aerosol](#)

[QVAR RediHaler \(beclomethasone dipropionate HFA\) inhalation aerosol](#)

[SYNRIBO \(omacetaxine\) for injection](#)

[TREANDA \(bedamustine\) for injection](#)

[TRISENOX \(arsenice trioxide\) injection](#)

[TRUXIMA \(rituximab-abbs\) injection](#)

Contact info-**Phone:** 877-237-4881 **Fax:** 877-438-4404

[Tolmar Total solutions](#)

Eligibility

US resident

<500% FPL

Uninsured

| Household size | Annual household income (\$) threshold (<u><500% FPL</u>) |
|----------------|---|
| 1 | 67,950 |
| 2 | 91,550 |

| | |
|----------|--|
| 3 | 115,150 |
| 4 | 138,750 |
| ≥ 5 | Click for FPL for household larger than 5 or add 23,600 per each additional person |

a. Proof of income **required**

Medications eligible for assistance

[Eligard \(leuprolide\)](#)

Contact info-**Phone:** 1-844-TOLMAR1 **Fax:** 1-844-TOLMAR2

Veltassa Konnect

Eligibility

US resident

$\leq 500\%$ FPL

Uninsured

| Household size | Annual household income (\$) threshold ($\leq 500\%$ FPL) |
|----------------|--|
| 1 | 67,950 |
| 2 | 91,550 |
| 3 | 115,150 |
| 4 | 138,750 |
| ≥ 5 | Click for FPL for household larger than 5 or add 23,600 per each additional person |

a. **Requires** copy of **ONE** of the following:

- i. Federal tax return
- ii. Pay stub
- iii. W-2 statement
- iv. Bank statement or other source of income information

Medications eligible for assistance

[Veltassa \(patiromer\)](#)

Contact info-**Phone:** 1-8888-623-7092 **Fax:** 1-888-623-7092

PAPs by Disease State/Condition

ANTI-MIGRAINE

Medications available for assistance

[Aimovig \(Erenumab\)](#)

[Botox \(Onabotulinumtoxina\)](#)

[Emgality® \(Galcanezumab-Gnlm\) Injection](#)

[Imitrex \(Sumatriptan Nasal Spray\)](#)

[QULIPTA \(Atogepant\) Tablets](#)

[Relpax \(Eletriptan\)](#)

[Relpax® \(Eletriptan Hydrobromide\) Tablets](#)

[Revvow® \(Lasmiditan\) Tablets C-V](#)

[Ubrelvy \(Ubrogepant\) Tablets](#)

Antithrombotics

| Medication class | Medication name |
|------------------|---|
| Anticoagulant | <u>Arixtra (Fondaparinux)</u> |
| | <u>Eliquis® (Apixaban)</u> |
| | <u>Fragmin® (Dalteparin Sodium) Injection</u> |
| | <u>Heparin Sodium Injection, USP</u> |
| | <u>Lovenox® (Enoxaparin Sodium Injection)</u> |
| | <u>Pradaxa (Dabigatran)</u> |
| Antiplatelet | <u>Xarelto (Rivaroxaban) Tablets Or Oral Solution</u> |
| | <u>Brilinta (Ticagrelor)</u> |
| Clotting factor | <u>Benefix® Coagulation Factor IX (Recombinant)</u> |
| Thrombolytic | <u>Activase (Alteplase)</u> |
| | <u>Cathflo Activase (Alteplase)</u> |
| | <u>TNKase (Tenecteplase)</u> |

Direct acting oral anticoagulants (DOACs) considerations

Eliquis and Xarelto programs exist. For our uninsured patients, the following should be known:

- Xarelto program allows for the patient to check the Box in Section 4, which will allow the company to run a credit check/proof of income on their own **or** the patient provide their most recent 1040 or 1040-SR Federal tax return if available.
 - Annual Income for single person household needs to be **less than \$40,770**
 - The Xarelto program sends the patient a pharmacy card, which will include an ID, RxBIN and Rx Group code that is good for one year and will cover the cost of the medication
- Eliquis program states “Proof of income may be required”: would like most recent federal tax return. If not available, it states provide as many of the following as possible:
 - W2
 - 1099

- Pension statement
- Social security statement
- At least 2 consecutive pay stubs
- Annual household income needs to be **less than \$40,770**

AUTOIMMUNE DISORDERS

| Medications available for assistance | Disease state |
|---|---|
| Actemra (Tocilizumab) | Rheumatoid arthritis |
| Adakveo® (Crizanlizumab-Tmca) | Sickle cell |
| Avsola (Infliximab-Axxq) | Plaque psoriasis, Crohn's, Ulcerative colitis, Rheumatoid arthritis |
| Benlysta (Belimumab) | Lupus nephritis |
| BETASERON (interferon beta-1b) | Multiple sclerosis, relapsing |
| Canasa (Mesalamine) Suppository | Crohn's, Ulcerative colitis |
| Cibinquo™ (Abrocitinib) Tablets | Atopic dermatitis |
| Cosentyx® (Secukinumab) | Plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis |
| CREON (Pancrelipase) Delayed-Release Capsules | Pancreatic insufficiency |
| Cyclosporine Capsules Modified | Transplant, Rheumatoid arthritis, Psoriasis |
| Cyclosporine Oral Solution Modified | Transplant, Rheumatoid arthritis, Psoriasis |
| Cystagon (Cysteamine) Capsules | Nephropathic cystinosis |
| Delzicol (Mesalamine Dr) Capsules | Crohn's, Ulcerative colitis |
| Depen (Penicillamine) Tablets | Wilson's disease, cystinuria |
| Dipentum (Olsalazine) Capsule | Crohn's, Ulcerative colitis |
| Enbrel (Etanercept) | Plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis |
| Enspryng (Satralizumab-Mwge) | Neuromyelitis optica spectrum disorder |
| Esbriet (Pirfenidone) | Idiopathic pulmonary fibrosis |
| Evrysdi (Risdiplam) | Spinal muscular atrophy |
| Extavia® (Interferon Beta-1B) | Multiple sclerosis, relapsing |
| Gengraf Capsules (Cyclosporine, USP [Modified]) | Transplant, Rheumatoid arthritis, Psoriasis |
| Genotropin® (Somatropin) For Injection | Growth hormone deficiency or failure (pediatrics) |
| Gilenya® (Fingolimod) | Multiple sclerosis, relapsing |
| Glatiramer Acetate | Multiple sclerosis, relapsing |
| Hemlibra (Emcizumab-Kxwh) | Hemophilia A, prophylaxis |
| Humatrope® (Somatropin) For Injection | Growth hormone deficiency or failure (pediatrics) |

[RETURN TO TOP](#)

| | |
|--|---|
| Humira (Adalimumab) | Plaque psoriasis, Crohn's, Ulcerative colitis, Rheumatoid arthritis |
| ILARIS® (Canakinumab) | Adult onset Still's disease, Periodic fever syndromes |
| Inflectra® (Infliximab-Dyyb) For Injection | Plaque psoriasis, Crohn's, Ulcerative colitis, Rheumatoid arthritis |
| Lialda (mesalamine) DR tablets | Crohn's, Ulcerative colitis |
| Mavyret (Glecaprevir/Pibrentasvir) | Chronic hepatitis C |
| Mayzent® (Siponimod) | Multiple sclerosis |
| Mozobil® (Plerixafor Injection) | Peripheral stem cell mobilization |
| Nplate (Romiplostim) | Immune thrombocytopenia |
| Nulojix® (Belatacept)) | Kidney transplant (de novo use) |
| Ocrevus (Orelizumab) | Multiple sclerosis, relapsing or primary progressive |
| Ofev (Nintedanib) | Idiopathic pulmonary fibrosis |
| Olumiant® (Baricitinib) Tablets | Rheumatoid arthritis |
| Omnitrope® Somatropin (Rdna Origin) | Growth hormone deficiency or failure (pediatrics) |
| Orencia® (Abatacept) | Graft vs host disease, Psoriatic arthritis, Rheumatoid arthritis |
| Otezla (Apremilast) | Psoriasis, Psoriatic arthritis, Bechet disease |
| Pegasys (Peginterferon Alfa-2A) | Chronic hepatitis B |
| Pentasa (mesalamine) ER capsules | Crohn's, Ulcerative colitis |
| Ponvory (Ponesimod) | Multiple sclerosis, relapsing |
| Promacta® (Eltrombopag) | Immune thrombocytopenia |
| Rapamune® (Sirolimus) | Renal transplant, lymphangioleiomyomatosis |
| Reblozyl® (LUSPatercept-Aamt) | Anemia due to myelodysplastic syndromes |
| Remicade (Infliximab) IV Infusion | Plaque psoriasis, Crohn's, Ulcerative colitis, Rheumatoid arthritis |
| Rinvoq (Upadacitinib) | Psoriatic arthritis, Atopic dermatitis, Ulcerative colitis, Rheumatoid arthritis |
| Rituxan (Rituximab) For Rheumatoid Arthritis | Rheumatoid arthritis |
| Rowasa (Mesalamine) Rectal SUSPension | Crohn's, Ulcerative colitis |
| Saphnelo (Anifrolumab-Fnia) | Systemic lupus erythematosus, moderate to severe |
| Sf Rowasa (Mesalamine) Rectal SUSPension | Crohn's, Ulcerative colitis |
| Simponi (Golimumab) Injection | Psoriatic arthritis, Ankylosing spondylitis, Ulcerative colitis, Rheumatoid arthritis |
| Skyrizi (Risankizumab-Rzaa) | Plaque psoriasis, Psoriatic arthritis |
| Somavert® (Pegvisomant) For Injection | Acromegaly |
| SOTYKTU (deucravacitinib) | Plaque Psoriasis |

| | |
|--|---|
| Stelara (Ustekinumab) For Subcutaneous Or Iv Use | Crohn's, Plaque psoriasis, Psoriatic arthritis, Ulcerative colitis |
| Taltz® (Ixekizumab) Injection | Ankylosing spondylitis, Plaque psoriasis, Psoriatic arthritis |
| Tremfya (Guselkumab) For Subcutaneous Use | Plaque psoriasis, Psoriatic arthritis |
| Truxima (Rituximab-Abbs) Injection | Rheumatoid arthritis |
| Viokace (Pancrelipase) Tablets | Pancreatic insufficiency |
| Vyndaqel® (Tafamidis Meglumine) Capsules | Amyloid cardiomyopathy |
| Xeljanz® (Tofacitinib) Oral Solution | Ankylosing spondylitis, Plaque psoriasis, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis |
| Xeljanz® (Tofacitinib) Tablets | |
| Xeljanz® Xr (Tofacitinib) Extended-Release Tablets | |
| Xyntha® Antihemophilic Factor (Recombinant) | Hemophilia A |
| Zenpep (Pancrelipase) Delayed Release Capsule | Pancreatic insufficiency |
| Zeposia® (Ozanimod) | Multiple sclerosis, relapsing |

CARDIOVASCULAR

Medications available for assistance

[Adempas \(riociguat\)](#)

[BiDil \(isosorbide dinitrate/hydralazine\)](#)

[Bystolic \(Nebivolol\) Tablets](#)

[Caduet \(Amlodipine/Atorvastatin\)](#)

[CAMZYOS \(mavacamten\)](#)

[Corlanor \(Ivabradine\)](#)

[Edarbi \(azilsartan medoxomil\)](#)

[Edarbyclor \(azilsartan medoxomil/chlorthalidone\)](#)

[Entresto™ \(Sacubitril/Valsartan\)](#)

[Farxiga \(Dapagliflozin\)](#)

[Inspira \(Eplerenone\)](#)

[Jardiance \(Empagliflozin\)](#)

[Kerendia \(finerenone\)](#)

[Leqvio® \(Inclisiran\)](#)

[Lokelma \(Sodium Zirconium Cyclosilicate\)](#)

[Multaq® \(Dronedarone\) Tablets](#)

[Norpace® \(Disopyramide Phosphate\)](#)

[Nymalize \(nimodipine oral solution\)](#)

[Opsumit \(Macitentan\) Tablets](#)

[Praluent \(alirocumab\)](#)

[Repatha \(Evolocumab\)](#)

[Sotylose \(sotalol oral solution\)](#)

[Tikosyn® \(Dofetilide\) Capsules](#)

[Tracleer \(Bosentan\)](#)

[Uptravi \(Selexipag\)](#)

[Veletri \(Epoprostenol\)](#)

[Ventavis \(Iloprostol\)](#)

[Verquvo™ \(Vericiguat\) 2.5 Mg, 5 Mg, 10 Mg Tablets](#)

[Veltassa \(patiromer\)](#)

Cardiovascular medications: Entresto (Manufactured by Novartis)

For Novartis products including Entresto eligibility for full patient assistance as follows:

- Household income per year:

| Household size | Annual household income (\$) threshold |
|----------------|--|
| 1 | 70,000 |
| 2 | 100,000 |
| 3 | 125,000 |
| 4 | 150,000 |
| ≥5 | Add 25,000 per additional person |

- Uninsured or limited private or public prescription coverage
- Patient will need to allow electronic income check, which will not affect credit score, only used to verify income by checking the box on page 3 under section 3 OR provide the following:
 - Most recent federal tax return
 - W-2 form
 - 3 months of paycheck stubs
 - Social security statement (1099)
- Prescriber application is page 4 and requires and ICD-10 code along with prescription, and prescriber signature

*****If patient has commercial insurance, \$10 copay card is available along with free 30-day trial*****

- Will need patient's Prescription insurance card with the following information
 - Rx BIN
 - Rx Group (GRP)
 - Rx PCN

[For prior authorizations for Entresto](#)

Three easy steps:

1. Select the patient's insurance provider (Commercial, Medicare, and Medicaid comprehensive list on website)
2. Review the coverage details and PA requirements for selected insurance plan (Aetna Standard example provided) – Not requiring a PA

2

Review Coverage Details for ENTRESTO

Learn about the coverage information and PA requirements for the plan you selected.

Aetna Standard

► COVERAGE

| | |
|---------------------------------|-----------------------------------|
| State: South Carolina | Name of Payer: Aetna, Inc. |
| Type of Plan: Commercial | PA Required?: No |
| Formulary Tier: Preferred Brand | Number of Formulary Tiers: 6-Tier |
| Step Therapy Required?: No | Step Therapy Placement: |
| Quantity Limits: No | |

| | |
|----------------------------------|--|
| PA Requirements | |
| NYHA Class Requirements | |
| LVEF Requirements | |
| Specialist Approval Required? | |
| Concomitant Therapy Requirements | |
| Proof of Effectiveness Required? | |
| Lab Requirements | |
| Dose Limits | |
| Length of Initial Authorization | |

LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.

The coverage and prior authorization (PA) requirements listed here are representations by Zitter Health Insights of the actual criteria developed and approved by managed care organizations and are not controlled by Novartis Pharmaceuticals Corporation (NPC). Coverage information is subject to change by the relevant plan. NPC has not independently verified the requirements of each plan and assumes no responsibility for this content. NPC cannot guarantee payment of any claim. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims. It is the sole responsibility of the health care provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement.

Please note: In this tool, qualified health plans available through health insurance marketplaces are considered commercial plans.

Reference: Data on file. Zitter Health Insights. Policy & Access Tracking Tool. Novartis Pharmaceuticals Corp. East Hanover, NJ.

See Absolute Total Care example which does require a PA

2

Review Coverage Details for ENTRESTO

Learn about the coverage information and PA requirements for the plan you selected.

Absolute Total Care

► COVERAGE

| | |
|------------------------------------|------------------------------------|
| State: South Carolina | Name of Payer: Centene Corporation |
| Type of Plan: Medicaid | PA Required?: Yes |
| Formulary Tier: Preferred Brand | Number of Formulary Tiers: Closed |
| Step Therapy Required?: No | Step Therapy Placement: |
| Quantity Limits: 2 tablets per day | |

► PA INFORMATION

| | |
|----------------------------------|---|
| PA Requirements | Meets below requirements |
| NYHA Class Requirements | NYHA Class II-IV |
| LVEF Requirements | Left ventricular ejection fraction (LVEF) is = 40% |
| Specialist Approval Required? | Cardiologist |
| Concomitant Therapy Requirements | No |
| Proof of Effectiveness Required? | Show Response |
| Lab Requirements | Left ventricular ejection fraction (LVEF) is = 40% |
| Dose Limits | Dose does not exceed sacubitril 194 mg/valsartan 206 mg (2 tablets for adults) per day. |
| Length of Initial Authorization | 1 PlanYear |

LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.

The coverage and prior authorization (PA) requirements listed here are representations by Zitter Health Insights of the actual criteria developed and approved by managed care organizations and are not controlled by Novartis Pharmaceuticals Corporation (NPC). Coverage information is subject to change by the relevant plan. NPC has not independently verified the requirements of each plan and assumes no responsibility for this content. NPC cannot guarantee payment of any claim. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims. It is the sole responsibility of the health care provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement.

Please note: In this tool, qualified health plans available through health insurance marketplaces are considered commercial plans.

Reference: Data on file. Zitter Health Insights. Policy & Access Tracking Tool. Novartis Pharmaceuticals Corp. East Hanover, NJ.

If no PA is required, you can proceed with prescribing the medication. If PA Is required, proceed to step 3, which takes your directly to the PA form

3

Access the Plan-Specific PA Form for ENTRESTO

Click on the link to access the plan's PA form. If you have questions about submitting the form, please visit CheckBenefitsNow.com.

[Access PA Form](#)
[More PA Information](#)

Diabetes

| Medication class | Medication name |
|---------------------|--|
| DPP4 inhibitor | Januvia® (Sitagliptin) Tablets |
| | Nesina (alogliptin) tablets |
| | Onglyza (Saxagliptin) |
| | Tradjenta (Linagliptin) |
| GLP-1 | Bydureon (Exenatide Extended Release) |
| | Byetta (Exenatide) |
| | Ozempic (Semaglutide) Injection |
| | Rybelsus (Semalglutide) Tablets |
| | Trulicity® (Dulaglutide) Injection |
| | Victoza (Liraglutide) Pen |
| GLP-1 insulin combo | Soliqua® 100/33 (Insulin Glargine & Lixisenatide) Injection 100 Units/mL And 33 Mcg/mL |
| | Xultophy (Insulin Degludec & Liraglutide) Pen |
| Insulin | |
| Rapid acting | Admelog® (Insulin Lispro Injection) 100 Units/mL |
| | Apidra® (Insulin Glulisine Injection) 100 Units/mL |
| | Fiasp FlexTouch (Insulin Aspart) |
| | Humalog® U-100 (Insulin Lispro Injection) |
| | Humalog® U-200 (Insulin Lispro Injection) |
| | Lyumjev™ (Insulin Lispro-Aabc) Injection |
| Short acting | Novolog (Insulin Aspart) FlexPen |
| | Humulin® R (Insulin Human Injection) |
| | Humulin® R U-500 (Insulin Human Injection) |
| Intermediate acting | Novolin R Vial (Insulin Regular) |
| | Humulin® N (Isophane Insulin Human SUSPension) |
| Long acting | Novolin N Vial (Insulin Nph) |
| | Basaglar® (Insulin Glargine Injection) |
| | Lantus® (Insulin Glargine Injection) 100 Units/mL |
| | Levemir (Insulin Detemir) FlexTouch |
| | Semglee (Insulin Glargine) |
| | Toujeo® (insulin glargine injection) 300 Units/mL (1.5 mL or 3.0 mL pens) |
| | Tresiba (Insulin Degludec) FlexTouch |
| Mixed insulin | |

| | |
|-------------------------|---|
| | <u>Humalog® Mix50/50™ (Insulin Lispro Protamine And Insulin Lispro Injectable Suspension)</u> |
| Rapid/Intermediate | <u>Humalog® Mix75/25™ (Insulin Lispro Protamine And Insulin Lispro Injectable Suspension)</u> |
| | <u>Novolog Mix 70/30 (Insulin Aspart Protamine And Insulin Aspart) Flexpen</u> |
| Regular/Intermediate | <u>Humulin® 70/30 (Human Insulin Isophane SUSPension And Human Insulin Injection)</u> |
| | <u>Novolin 70/30 (Insulin Nph And Insulin R Mix) Vial</u> |
| SGLT-2 inhibitor | <u>Faxigia (Dapagliflozin)</u> |
| | <u>Invokana (Canagliflozin)</u> |
| | <u>Jardiance (Empagliflozin)</u> |
| | Combination oral |
| SGLT2/metformin | <u>Glyxambi (Empagliflozin/Metformin)</u> |
| | <u>Invokamet (Canagliflozin/Metformin)</u> |
| | <u>Invokamet Xr (Canagliflozin/Metformin Xr)</u> |
| | <u>Synjardy & Synjardy Xr (Empagliflozin/Metformin)</u> |
| | <u>Xigduo Xr (Dapagliflozin/Metformin Er)</u> |
| DPP4/metformin | <u>Janumet® (Sitagliptin And Metformin Hci) Tablets</u> |
| | <u>Janumet® Xr (Sitagliptin And Metformin Hci Extended-Release) Tablets</u> |
| | <u>Jentadueto & Jentadueto Xr (Linagliptin/Metformin)</u> |
| | <u>Kazano (alogliptin/metformin) tablets</u> |
| | <u>Kombiglyze Er (Saxagliptin/Metformin Er)</u> |
| DPP4/SGLT2 | <u>Qtern (Dapagliflozin/Saxagliptin)</u> |
| DPP4/metformin/SGLT2 | <u>Trijardy Xr (Empagliflozin/Linagliptin/Metformin)</u> |
| DPP4/TZD | <u>Oseni (alogliptin/pioglitazone) tablets</u> |
| Other | <u>Symlin (Pramlintide)</u> |
| Hypoglycemia management | <u>Baqsimi® (Glucagon) Nasal Powder</u> |
| | <u>Glucagon™ (Glucagon For Injection)</u> |
| | <u>Glucagen Hypokit</u> |

Diabetic medications: Insulin, GLP-1 agonists, SGLT2 inhibitors

Example of workflow for Lilly Cares

There is an application through Lilly Cares for **free Basaglar and Humalog** for financially constrained patients.

The steps for completion are as follows:

1. Pharmacist or case manager can have the patient fill out the information of name, address, phone number, DOB, etc.

- a. Patient qualifies if single person home annual income <\$54,360 and **no insurance or Medicare Part D**. If larger household, see application for further details
2. Provider signs actual prescription in the application packet (page 5) and additional signature (page 6)
3. Patient provides W2 or if no W2 available, handwritten provider note on McLeod letter head stating what the patient's annual income is/financial situation will be sufficient
4. Application faxed to number provided on Lilly cares application (3-7 days to process)

5. Case management will have to assist patient with first time fill at McLeod Outpatient Pharmacy (\$35.00 coupon attached to email), pen needles, lancets, test strips, glucometer (can be provided by diabetic educator if ordered)

As of June 29th of 2021, Walmart has produced a **Novolog** of their own. I called Walmart and confirmed all of the pricing with one of their pharmacists (see table below)

| Relion brand at Walmart | Insulin type | Vial (\$) | FlexPen (\$) |
|--------------------------------|---|------------------|---------------------|
| Novolog | Rapid | 72.88 | 85.88 |
| Regular (Novolin R) | Short acting | 24.88 | 42.88 |
| 70/30 premix (Novolin 70/30) | Intermediate combined with short acting | 24.88 | 42.88 |
| NPH (Novolin N) | Intermediate | 24.88 | 42.88 |

SGLT2 inhibitor (Farxiga-dapagliflozin or Jardiance-empagliflozin)

2. Farxiga-dapagliflozin (AstraZeneca)
 - a. Commercially insured
 - i. Use \$0.00 copay card
 1. Rx BIN: 004682
 2. PCN: CN
 3. GRP: EC57010026
 4. ID: 415132769337
3. Jardiance-empagliflozin (Boehringer Ingelheim)
 - a. Commercial insurance
 - i. [Select medication, dose, and indication \(diabetes vs heart failure\)](#)
 - ii. Fill in patient information
 - iii. Submit for \$10 copay card

INFECTIOUS DISEASE (HIV & Acute)

Medications available for assistance

ACUTE

[Avycaz \(Avibactam/Ceftazidime\)](#)

[Boostrix \(Tdap Vaccine\)](#)

[Cancidas® \(Caspofungin Acetate\) For Injection](#)

[Coartem® \(Artemether And Lumefantrine\)](#)

[Dalvance \(Dalbavancin\) Lyophilizate](#)

[Dificid® \(Fidaxomicin\) For Oral SUSPension 40 Mg/mL](#)

[Dificid® \(Fidaxomicin\) Tablets](#)

[Engerix-B \(Hepatitis B Vaccine\)](#)

| |
|--|
| Extavia® (Interferon Beta-1B) |
| Gardasil®9 (Human Papillomavirus 9-Valent Vaccine, Recombinant) |
| Imogam® Rabies-Ht Immune Globulin, [Human] USP, Heat Treated |
| Imovax® Rabies Vaccine [Human Diploid Cell] |
| Lincocin® (Lincomycin) Injection, USP |
| Malarone (Atovaquone And Proguanil) |
| Mavyret (Glecaprevir/Pibrentasvir) |
| Menquadfi® (Meningococcal [Groups A, C, Y, W] Conjugate Vaccine) |
| Mepron (Atovaquone SUSPension) |
| M-M-R® Ii (Measles, Mumps, And Rubella Virus Vaccine Live) |
| Monurol (Fosfomycin Tromethamine) Oral Granules |
| Mycobutin® (Rifabutin) Capsules, USP |
| Noxafil® (Posaconazole) Delayed-Release Tablets 100 Mg |
| Noxafil® (Posaconazole) Oral SUSPension, 40 Mg/Ml |
| Pegasys (Peginterferon Alfa-2A) |
| Pentacel® Diphtheria And Tetanus Toxoids And Acellular Pertussis Adsorbed, Inactivated Poliovirus And Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine |
| Pretomanid Tablet |
| Prevnar 13® Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria CRM197 Protein] |
| Prevymis™ (Letermovir) 240 Mg Tablets |
| Priftin® (Rifapentine) Tablets |
| Pylera (Bismuth Subcitrate Potassium, Metronidazole, And Tetracycline) Capsules |
| Recarbio™ (Imipenem, Cilastatin, And Relebactam) For Injection, For Intravenous Use |
| Recombivax Hb® [Hepatitis B Vaccine (Recombinant)] |
| Relenza (Zanamivir Inhalation Powder) |
| Shingrix (Zoster Vaccine) |
| Sirturo (Bedaquiline) Tablets |
| Sporanox (Itraconazole) Capsules And Oral Solution |
| Stromectol® (Ivermectin) Tablets |
| Teflaro (Ceftaroline Fosamil) Powder For Injection |
| Tenivac® (Tetanus And Diphtheria Toxoids Adsorbed) |
| Tobi (Tobramycin) Ampules Or Podhalers |
| Trumenba® (Meningococcal Group B Vaccine) |
| Tygacil® (Tigecycline) For Injection |
| Vaqta® (Hepatitis A Vaccine, Inactivated) |
| Varivax® (Varicella Virus Vaccine Live) |
| Vaxneuvance™ (Pneumococcal 15-Valent Conjugate Vaccine) |

[Vfend® \(Voriconazole\)](#)

[Zepatier® \(Elbasvir And Grazoprevir\)](#)

[Zerbaxa™ \(Ceftolozane And Tazobactam\) For Injection For Intravenous Use](#)

[Zyvox® \(Linezolid\)](#)

HIV

[Cimduo \(Lamivudine/Tenofovir Disoproxil Fumarate\) Tablet](#)

[Delstrigo™ \(Doravirine, Lamivudine, And Tenofovir Disoproxil Fumarate\) Tablets, For Oral Use](#)

[Edurant \(Rilpivirine\) Tablets](#)

[Epivir-Hbv \(Lamivudine Solution Or Tablets\)](#)

[Intelence \(Etravirine\) Tablets](#)

[Isentress® \(Raltegravir\) 400 Mg Film-Coated And 25 Mg And 100 Mg Chewable Tablets](#)

[Isentress® Hd \(Raltegravir\) 600 Mg Tablets](#)

[Isentress® Os \(Raltegravir\) 100 Mg Granules For SUSPension](#)

[Kaletra \(Lopinavir/Ritonavir\)](#)

[Norvir \(Ritonavir\) Tablets And Oral Solution](#)

[Pifeltro™ \(Doravirine\) Tablets, For Oral Use](#)

[Pneumovax®23 \(Pneumococcal Vaccine Polyvalent\)](#)

[Prezcobix \(Darunavir/Cobicistat\)](#)

[Prezista \(Darunavir\)](#)

[Symtuza \(Darunavir, Cobicistat, Emtricitabine, Tenofovir Alafenamide\) Tablets](#)

[Viramune Xr \(Nevirapine\)](#)

HIV Resources for South Carolina

[South Carolina Aids Drug Assistance Program \(ADAP\)](#), which reimburses 100% of cost for qualifying patients

- Three services
 1. Direct dispensing program (DDP)
 - a. Receive HIV medication directly through mail-order pharmacy (PANTHERx Specialty)
 2. Insurance Assistance program (IAP)
 - a. Fill medications through health insurance, program assists with premiums, copays, and deductibles through network of approved pharmacies
 3. Medicare D assistance program
 - a. Receive HIV medication directly through mail-order pharmacy (PANTHERx Specialty)

Qualifications

- Ready to make commitment to being adherent to pharmacotherapy
- Diagnosed with HIV/AIDS
- SC resident
- Limited income (\leq 550% of FPL)

| Household size | Annual household income (\$) threshold |
|----------------|--|
| 1 | 74,745 |
| 2 | 100,705 |

| | |
|---|---------|
| 3 | 126,665 |
| 4 | 152,625 |
| 5 | 178,585 |
| 6 | 204,545 |
| 7 | 230,505 |
| 8 | 256,465 |

[Click for FPL for household larger than 8](#)

- Ineligible for Medicaid
- Ineligible for Medicare Part D **with Full Low Income Subsidy (FLIS)**

Risk of termination

- Not responding to SC ADAP letters in timely fashion
- Failing to submit recertification documentation on time
- Income exceeds 550% FPL
- Stops taking medication as prescribes
- Qualifies for Medicaid or Medicare Part D with FLIS
- Moves out of SC or incarcerated

Required documentation

- Proof of income is required for the enrollee and for each member of the household listed on the form

Income Documentation

Documentation for income includes the following:

- Salaries
- Business profits
- Veterans Benefits
- Wages
- Rents, Interest, Dividends
- Social Security cash benefits
- Net earnings from self-employment
- Unemployment compensation
- Workers compensation
- Royalties and Commissions
- Scholarships
- Alimony
- Tips
 - Most current pay stubs, W2, Federal Tax return, pension, unemployment compensation, social security benefits, alimony, child support, worker's compensation, wage statement, or employer letter on company letterhead dated, signed and including salary information are all acceptable
 - [Separate form for Zero or No Income certification](#)
- Clinical data
 - Date of diagnosis
 - Most recent CD4 count
 - Most recent viral load
- [Pharmacy selection form](#)
 - Participating pharmacies:

- AIDS Healthcare Foundation Pharmacy – 3025 Farrow Road; Columbia, SC 29203
- CarePlus Pharmacy – mail order pharmacy located in Columbia, SC
- Easley Healthmart Pharmacy - 401 Hillcrest Drive; Easley, SC 29640
- Hawthorne Pharmacy – 2761 Laurel Street; Columbia, SC
- Hawthorne Pharmacy – 1520-A Taylor Street; Columbia, SC
- Long's Drug Store – 600 Kilbourne Road; Columbia, SC
- Long's Drug Store – 1216 W Main Street; Lexington, SC
- MedExpress – mail order pharmacy located in Salisbury, NC
- PANTHERx Specialty Pharmacy – mail order pharmacy located in Pittsburgh, PA
- Pharmacy Innovations - 620 Congaree Road, Suite F; Greenville, SC
- Responsive Solutions – 4605 Oleander Drive, Suite 5; Myrtle Beach, SC

- Full list of pharmacies available below:

https://scdhec.gov/sites/default/files/media/document/IAP-Participating-Rx_8_2021.pdf

Undocumented patients living in SC with HIV

- There is a form that can be filled out for undocumented patients to qualify for the program:

<https://scdhec.gov/sites/default/files/media/document/d-1593.pdf>

All patients will need to fill out recertification form annually

See ADAP website for additional questions: <https://scdhec.gov/aids-drug-assistance-program>

AIDS Drug Assistance Program (ADAP) Formulary

HIV ANTIRETROVIRAL DRUGS

| Brand | Generic | Drug Class | Additional considerations |
|-----------|--|-----------------------|--|
| Aptivus | Tipranavir | Protease Inhibitor | |
| Biktarvy | bictegravir / emtricitabine / tenofovir alafenamide fumarate | Combination Treatment | Before prescribing, refer to the drug's full prescribing information. |
| Cimduo | lamivudine/tenofovir disoproxil fumarate | NRTI | Product carries a boxed warning for post-treatment acute exacerbations of hepatitis B. |
| Combivir | lamivudine / zidovudine | NRTI | |
| Complera | emtricitabine / rilpivirine / tenofovir disoproxil fumarate | Combination Treatment | Indicated as a complete regimen for treatment of HIV-1 infection: 1) In patients 12 years of age and older with no antiretroviral treatment history and with HIV-1 RNA less than or equal to 100,000 copies/mL at the start of therapy and 2) In certain virologically suppressed (HIV-1 RNA <50 copies/mL) patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen. |
| Delstrigo | doravirine / lamivudine/ tenofovir disoproxil fumarate | Combination Treatment | Product carries a boxed warning regarding the risk of post-treatment acute exacerbations of hepatitis B. Contraindicated when co-administered with drugs that are strong cytochrome P450 3A enzyme inducers (decreases in doravirine plasma concentrations may occur which may decrease the product's effectiveness). Refer to the package insert for concurrently administered drugs to avoid. Precautions include new onset or worsening renal impairment, risk of adverse reactions or loss of virologic response due to drug interactions, bone loss and mineralization defects, and Immune Reconstitution Syndrome. |

| | | | |
|---|--|-----------------------|--|
| Descovy | emtricitabine /tenofovir alafenamide | NRTI | |
| Dovato | dolutegravir / lamivudine | Combination Treatment | Dovato carries a Boxed Warning for patients co-infected with hepatitis B virus (HBV) and HIV-1. Prior to initiating treatment, patients should be tested for HBV infection. The emergence of HBV variants associated with resistance to lamivudine has been reported in HIV-1-infected patients who have received lamivudine-containing antiretroviral regimens in the presence of concurrent infection with HBV. In addition, severe exacerbations of HBV have been reported in patients co-infected with HIV-1 and HBV who have discontinued lamivudine. |
| Edurant | Rilpivirine | NNRTI | |
| efavirenz / emtricitabine / tenofovir disoproxil fumarate | efavirenz / emtricitabine / tenofovir disoproxil fumarate | Combination Treatment | Removed February 2022: Gilead Sciences discontinued the manufacturing of Atripla in July 2021. It is no longer available for commercial sale. |
| Emtriva | Emtricitabine | NRTI | |
| Epivir | Lamivudine | NRTI | |
| Epzicom | abacavir/ lamivudine | NRTI | Before adding an abacavir-containing medication to the drug regimen, refer to the drug's full prescribing information. |
| Evotaz | atazanavir / cobicistat | Combination Treatment | |
| Fuzeon | Enfuvirtide | Fusion Inhibitor | Prior authorization required for an individual's first ADAP prescription for this drug. |
| Genvoya | elvitegravir / cobicistat /emtricitabine / tenofovir alafenamide | Combination Treatment | |
| Intelence | Etravirine | NNRTI | |
| Invirase | Saquinavir | Protease Inhibitor | |
| Isentress, Isentress HD | Raltegravir | Integrase Inhibitor | |
| Juluca | dolutegravir / rilpivirine | Combination Treatment | Clinical information regarding dolutegravir: At this point, women with HIV who wish to become pregnant and are currently receiving dolutegravir should be switched to a regimen with a more well-defined safety record in pregnancy. Women with HIV who are of childbearing age and are not interested in having children should be counseled about this information. Women who become pregnant while on dolutegravir need to discuss options with their HIV providers. |
| Kaletra | lopinavir / ritonavir | Protease Inhibitor | |
| Lexiva | Fosamprenavir | Protease Inhibitor | |
| Norvir | Ritonavir | Protease Inhibitor | |
| Odefsey | emtricitabine / rilpivirine /tenofovir alafenamide fumarate | Combination Treatment | Indicated as a complete regimen for treatment of HIV-1 infection in patients 12 years of age and older as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies per mL; or to replace a stable antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) for at least six months with no history of treatment failure and no known substitutions associated with resistance to individual components of Odefsey. |
| | | | Contraindicated when co-administered with drugs that are |

| | | | |
|-------------------|---|------------------------------------|---|
| Pifeltro | Doravirine | NNRTI | strong cytochrome P450 3A enzyme inducers. Decreases in doravirine plasma concentrations may occur which may decrease the product's effectiveness. Refer to the package insert for concurrently administered drugs to avoid. Other warnings and precautions include risk of adverse reactions or loss of virologic response due to drug interactions and ImmuneReconstitution Syndrome. |
| Prezcobix | darunavir / cobicistat | Combination Treatment | |
| Prezista | Darunavir | Protease Inhibitor | |
| Retrovir | Zidovudine | NRTI | |
| Reyataz | Atazanavir | Protease Inhibitor | |
| Rukobia | Fostemsavir | GP120 Attachment Inhibitor | |
| Selzentry | Maraviroc | CCR5 Co-Receptor Antagonist | Prior authorization required for an individual's first ADAP prescription for this drug. |
| Stribild | elvitegravir / cobicistat /emtricitabine / tenofovirdisoproxil fumarate | Combination Treatment | |
| Sustiva | Efavirenz | NNRTI | |
| Symfi Symfi Lo | efavirenz / lamivudine / tenofovirdisoproxil fumarate | Combination Treatment | Product carries a boxed warning for post-treatment acute exacerbations of hepatitis B. |
| Syntuza | darunavir / cobicistat /emtricitabine / tenofoviralafenamide | Combination Treatment | |
| Tivicay | Dolutegravir | Integrase Inhibitor | Clinical information regarding dolutegravir: At this point, women with HIV who wish to become pregnant and are currently receiving dolutegravir should be switched to a regimen with a more well-defined safety record in pregnancy. Women with HIV who are of childbearing age and are not interested in having children should be counseled about this information. Women who become pregnant while on dolutegravir need to discuss options with their HIV providers. |
| Triumeq | abacavir / dolutegravir /lamivudine | Combination Treatment | Before adding an abacavir-containing medication to the drug regimen, refer to the full prescribing information. Clinical information regarding dolutegravir: At this point, women with HIV who wish to become pregnant and are currently receiving dolutegravir should be switched to a regimen with a more well-defined safety record in pregnancy. Women with HIV who are of childbearing age and are not interested in having children should be counseled about this information. Women who become pregnant while on dolutegravir need to discuss options with their HIV providers. |
| Trizivir | abacavir / lamivudine /zidovudine | NRTI | Before adding an abacavir-containing medication to the drug regimen, refer to the drug's full prescribing information. |
| Trogarzo | Ibalizumab-uiyk | CD4 post-attachmentHIV-1 inhibitor | Prior authorization is required for this medication. To initiate the process, please go through the Theratechnologies THERA patient support® program. Go to the website listed below and click on "I am a Healthcare Provider" and choose the Trogazo button. Then, look to the right of the next page for the Trogarzo Enrollment Form. https://www.therapatsupport.com |
| Truvada | emtricitabine /tenofovir disoproxil fumarate | NRTI | |
| Tybost | Cobicistat | Boosting Agent | Tybost should not be used with cobicistat-containing drugs such as Evotaz, Prezcobix, or Stribild. Tybost in combination with lopinavir/ritonavir or regimens containing ritonavir is not recommended due to similar effects of Tybost and ritonavir on CYP3A. Refer to the product's full prescribing information at https://www.gilead.com/science-and-medicine/medicines |

| | | | |
|--------------------|--------------|---------------------|---|
| Videx, Videx EC | Didanosine | NRTI | |
| Viracept | Nelfinavir | Protease Inhibitor | |
| Viramune | Nevirapine | NNRTI | |
| Viramune XR | Nevirapine | NNRTI | |
| Viread | Tenofovir | NRTI | |
| Vitekta | Elvitegravir | Integrase Inhibitor | Prior authorization required for an individual's first ADAP prescription for this drug. |
| Zerit | Stavudine | NRTI | |
| Ziagen | Abacavir | NRTI | Before adding abacavir to the drug regimen, refer to the drug's full prescribing information. |

Additional medications covered under ADAP for HIV associated comorbidities

OPPORTUNISTIC AND CO-INFECTION DRUGS

| Brand | Generic | Drug Class |
|--------------------------------------|--------------------------------------|-------------------------|
| Amoxicillin | Amoxicillin | Antibiotic |
| Augmentin | amoxicillin clavulanate | Antibiotic |
| Cipro | ciprofloxacin, oral | Antibiotic |
| Clarithromycin | Clarithromycin | Antibiotic |
| Cleocin | Clindamycin | Antibiotic |
| Clotrimazole | Clotrimazole | Antifungal |
| Clotrimazole / betamethasone topical | clotrimazole / betamethasone topical | Antifungal |
| Dapsone | Dapsone | Antibiotic |
| Diflucan | Fluconazole | Antifungal |
| Doxycycline monohydrate | doxycycline monohydrate | Antibiotic |
| Doxycycline hyclate | doxycycline hyclate | Antibiotic |
| Famciclovir | Famciclovir | Antiviral |
| Flagyl | metronidazole, oral | Antibiotic |
| Ketoconazole | ketoconazole tablets, topical | Antifungal |
| Leucovorin | Leucovorin | Opportunistic Infection |
| Levaquin | levofloxacin, oral | Antibiotic |
| Mepron | Atovaquone | Antiprotozoal |
| Moxifloxacin | moxifloxacin, oral | Antibiotic |
| Nystatin | Nystatin | Antifungal |
| Nystatin/triamcin acetonide | nystatin / triamcinolone topical | Antifungal |
| Relenza | Zanamivir | Antiviral |
| Ribavirin | Ribavirin | Antiviral |
| Sporanox | Itraconazole | Antifungal |
| Sulfadiazine | Sulfadiazine | Antibiotic |
| Sulfamethoxazole / trimethoprim | sulfamethoxazole / trimethoprim | Antibiotic |
| Tamiflu | Oseltamivir | Antiviral |
| Trimethoprim | Trimethoprim | Antibiotic |
| Valcyte | Valganciclovir | Antiviral |
| Valtrex | Valacyclovir | Antiviral |

[RETURN TO TOP](#)

| | | |
|-----------|--------------------|------------|
| Vfend | voriconazole, oral | Antifungal |
| Zithromax | Azithromycin | Antibiotic |
| Zovirax | Acyclovir | Antiviral |

ANTICONVULSANTS

| Brand | Generic | Drug Class |
|-----------|------------|----------------|
| Neurontin | Gabapentin | Anticonvulsant |

ANTIDEPRESSANT S

| Brand | Generic | Drug Class | Additional considerations |
|-------------------|-------------------------------|----------------|--|
| Amitriptyline | Amitriptyline | Antidepressant | |
| Celexa | Citalopram | Antidepressant | |
| Cymbalta | Duloxetine | Antidepressant | |
| Effexor XR | Venlafaxine | Antidepressant | |
| Lexapro | Escitalopram | Antidepressant | |
| Paxil | Paroxetine | Antidepressant | |
| Prozac | fluoxetine, daily formulation | Antidepressant | Prozac Weekly is not on the formulary. |
| Remeron | Mirtazapine | Antidepressant | |
| Trazodone | Trazodone | Antidepressant | |
| Wellbutrin XL, SR | Bupropion | Antidepressant | |
| Zoloft | Sertraline | Antidepressant | |

ANTIEMETIC AGENTS

| Brand | Generic | Drug Class |
|--------------------|--------------|------------|
| Promethazine | Promethazine | Antiemetic |
| Zofran, Zofran ODT | Ondansetron | Antiemetic |

ANTILOPHEMIC AGENTS

| Brand | Generic | Drug Class |
|-----------|--------------|-------------------|
| Crestor | Rosuvastatin | Antilipemic Agent |
| Pravachol | Pravastatin | Antilipemic Agent |
| Zocor | Simvastatin | Antilipemic Agent |

ANTITUBERCULOSIS AGENTS

| Brand | Generic | Drug Class |
|-----------|------------|----------------------|
| Myambutol | Ethambutol | Antitubercular Agent |
| Mycobutin | Rifabutin | Antitubercular Agent |

HIV-ASSOCIATED LIPODYSTROPHY

| Brand | Generic | Drug Class | Additional considerations |
|-------|---------|------------|---------------------------|
| | | | |

| | | | |
|------------|------------------|---|--|
| Egrifta SV | Tesamorelin | Growth Hormone Releasing Factor | Prior authorization is required for this medication. To initiate the process, please go through the Theratechnologies THERA patient support® program. Go to the website listed below and click on "I am a Healthcare Provider" and choose the Egrifta SVbutton. Then, look to the right of the next page for the Egrifta SV Enrollment Form. |
| | | https://www.therapatientssupport.com | |
| Prednisone | prednisone, oral | Steroid | |

SMOKING CESSATION PRODUCTS

South Carolina Tobacco Quitline: 1-800-QUIT-NOW

| Brand | Generic | Drug Class | Additional considerations |
|-------------|----------------------------------|-------------------|---|
| Chantix | varenicline tablet | Smoking Cessation | Tobacco users have a better chance at quitting with a treatment regimen inclusive of medications and counseling. Visit this webpage for information to assist patients with tobacco cessation: https://www.scdhcc.gov/health/tobacco-cessation |
| NicoDerm CQ | nicotine patch | Smoking Cessation | |
| Nicorette | nicotine polacrilex gum, lozenge | Smoking Cessation | |
| Nicotrol | nicotine inhaler, spray | Smoking Cessation | |
| Zyban | bupropion tablet | Smoking Cessation | |

<https://scdhecc.gov/sites/default/files/media/document/ADAP-Formulary-03-01-2022.pdf>

ADAP Pharmacy Phone Number: 855-PANTHRX (803-728-3212)

One month supplies are the dispense quantities through ADAP

Inhalers

| Medication class | Medication name |
|------------------|---|
| ICS ⁺ | Arnuity Ellipta (Fluticasone) |
| | Flovent (Diskus Or Hfa) (Fluticasone) |
| | Pulmicort Flexhaler (Budesonide) |
| | Qvar Redihaler (Beclomethasone Dipropionate Hfa) Inhalation Aerosol |
| ICS (nasal) | Beconase Aq (Beclomethasone Dipropionate Nasal Spray) |
| | Dymista (Azelastine/Fluticasone) Nasal Spray |
| | Qnasl (Beclomethasone) Nasal Aerosol |
| LAMA/LABA | Anoro Ellipta (Umeclidinium/Vilanterol) |
| | Bevespi Aerosphere (Glycopyrrolate/Formoterol) |
| | Stiolto Respimat (Tiotropium/Olodaterol) |
| LABA/ICS | Advair (Diskus Or Hfa) (Fluticasone/Salmeterol) |
| | Breo Ellipta (Fluticasone/Vilanterol) |
| | Symbicort (Budesonide/Formoterol) |
| | Wixela (Fluticasone/Salmeterol) |
| LABA* | Perforomist (Formoterol Fumarate) Inhalation Solution |

[RETURN TO TOP](#)

| | |
|---------------|---|
| | Serevent (Diskus) (Salmeterol) |
| | Striverdi Respimat (Olodaterol) |
| LAMA | Incruse Ellipta (Umeclidinium) |
| | Spiriva Handihaler Or Respimat (Tiotropium) |
| | Yupelri (Reverfenacin) |
| LAMA/LABA/ICS | Breztri Aerosphere (Budesonide/Glycopyrrolate/Formoterol) |
| SABA/SAMA | Combivent Respimat (Ipratropium/Albuterol) |
| SABA | Proair Hfa (Albuterol Sulfate) Inhalation Aerosol |
| | Proair Respiclick (Albuterol Sulfate) Inhalation Aerosol |
| SAMA | Atrovent Hfa (Ipratropium) |
| | Aerochamber Plus Flow-Vu |
| | Daliresp (Roflumilast) |
| | Pulmozyme (Dornase Alfa) Inhalation Solution |
| | Xolair (Omalizumab) |
| Other | Fasenra (Benralizumab) |
| | Fasenra Pen (Benralizumab) |
| | Nucala (Mepolizumab) |
| | + Not to be prescribed as monotherapy in COPD |

* Not to be prescribed as monotherapy in Asthma

ICS=inhaled corticosteroid, LABA=long acting beta agonist, LAMA=long acting muscarinic antagonist, SABA=short acting beta agonist, SAMA=short acting muscarinic antagonist

NEUROLOGY & PSYCHIATRY

Medications available for assistance

[APLENZIN \(bupropion hydrobromide\) Extended-Release Tablets](#)

[Aptiom® \(eslicarbazepine acetate\)](#)

[Belsomra® \(Suvorexant\) C-IV](#)

[Carbatrol \(carbamazepine extended-release\) capsules](#)

[Chantix® \(Varenicline\) Tablets](#)

[Celontin® \(Methsuximide\) Capsules, USP](#)

[Clozapine](#)

[CYCLOSET \(bromocriptine mesylate tablets\)](#)

[Depakote \(Divalproex Sodium\)](#)

[Dilantin® \(Extended Phenytoin Sodium\) Capsules](#)

[Felbatol \(Felbamate\)](#)

| |
|---|
| Fetzima (Levomilnacipran) Extended Release Capsules And Titration Pack |
| Gabitril (Tigabine Hydrochloride) Tablets |
| Haldol Decanoate (Haloperidol) Im Injection Only |
| Horizant (gabapentin encarbil) |
| Intuniv (guanfacine) ER tablets |
| Invega Sustenna, Trinza And Hafyera (Paliperidone Palmitate) Extended-Release Injection |
| Lamictal (Lamotrigine Chewable Or Orally Disintegrating Tablets) |
| Lamictal ODT (Lamotrigine Patient Titration Kits) |
| Lamictal Xr (Lamotrigine Er Or Patient Titration Kit) |
| Lexapro (Escitalopram) |
| Mydayis (amphetamine) ER capsules |
| NUPLAZID (pimavanserin) |
| Nicotrol® (Nicotine) |
| Pristiq® (Desvenlafaxine) Extended-Release Tablets |
| Prozac® (Fluoxetine Capsules) |
| Rexulti (Brexpiprazole) Tablets |
| Risperdal Consta (Risperidone) Long-Acting Injection |
| Rozerem (ramelteon) tablets |
| Saphris (Asenapine Maleate) Sublingual Tablet |
| Savella (Milnacipran) Tablets |
| Strattera® (Atomoxetine) Capsules |
| Symbax® (Olanzapine And Fluoxetine) Capsules |
| Trintellix (vortioxetine tablets) |
| Viibryd (Vilazodone) |
| Vraylar (Cariprazine) Capsules |
| Vyvanse (lisdexamfetamine) capsules and tablets |
| Xanax® CIV (Alprazolam) Tablets |
| Zarontin® (Ethosuximide) |
| Zyprexa® (Olanzapine) Tablet |
| Zyprexa® Zydis® (Olanzapine) Tablet |

ONCOLOGY

Medications available for assistance

| |
|--|
| Abraxane® (Paclitaxel Protein-Bound Particles For Injectable SUSPension (Albumin-Bound)) |
| Afinitor Disperz® (Everolimus SUSPension) |
| Afinitor® (Everolimus) |

[Alcensa \(Alectinib\)](#)

[Alimta® \(Pemetrexed For Injection\)](#)

[Aliqopa \(copanlisib\)](#)

[Aranesp \(Darbepoetin Alfa\)](#)

[Aromasin® \(Exemestane\) Tablets](#)

[Avastin \(Bevacizumab\)](#)

[Balversa \(Erdafitinib\) Tablets](#)

[Bendeka \(Bendamustine\)](#)

[BESPONSA \(inotuzumab\)](#)

[Blenrep \(Belantamab\)](#)

[Blincyto \(Blinatumomab\)](#)

[BOSULIF \(bosutinib\)](#)

[BRAFTOVI \(encoarfenib\)](#)

[Calquence \(Acalabrutinib\)](#)

[CAMPTOSAR \(irinotecan\)](#)

[Cotellic \(Cobimetinib\)](#)

[Cyramza® \(Ramucirumab\) Injection](#)

[Darzalex \(Daratumumab\) Injection For Iv Infusion](#)

[Darzalex Faspro \(Daraumumab And Hyaluronidase-Fihj\) Injection For Subcutaneous Use](#)

[DAURISMO \(glasdegib\)](#)

[EFUDEX \(fluorouracil\) Topical Cream](#)

[Eligard \(leuprolide\)](#)

[ELLENCE \(epirubicin\)](#)

[EMCYT \(estrامustine\)](#)

[Emend® \(Aprepitant\) 80 Mg, 125 Mg Capsules](#)

[Emend® \(Aprepitant\) For Oral SUSPension 125 Mg](#)

[Emend® \(Fosaprepitant Dimeglumine\) For Injection 150 Mg](#)

[Empliciti® \(Elotuzumab\)](#)

[Epogen \(Epoetin Alfa\)](#)

[Erbitux® \(Cetuximab\) Injection](#)

[Erivedge \(Vismodegib\)](#)

[Erleada \(Apalutamide\) Tablets](#)

[Faslodex \(Fulvestrant\)](#)

[Fulphila \(Pegfilgastrim-Jmdb\)](#)

[Fulvestrant Injection, For Intramuscular Use](#)

[FYARRO \(sirolimus albumin-bound\) for injection](#)

[Gavreto \(Pralsetinib\)](#)

[Gazyva \(Obinutuzumab\)](#)

[Gilterif \(Afatinib\)](#)

[Granix \(Tbo-Filgrastim\) Injection](#)

[Herceptin \(Trastuzumab\)](#)

[Herceptin Hylecta \(Trastuzumab And Hyaluronidase-Oysk\)](#)

[Herzuma \(Trastuzumab-Pkrb\) Injection](#)

[Hycamtin® \(Topotecan Hydrochloride\) For Injection](#)

[Hycamtin® \(Topotecan\) Capsules](#)

[IBRANCE \(Palbociclib\)](#)

[IDAMYCIN \(idarubicin\)](#)

[IDHIFA® \(Enasidenib\)](#)

[Imbruvica \(Ibrutinib\) Capsules/Tablets](#)

[Imbruvica \(Ibrutinib\)](#)

[Imfinzi \(Durvalumab\)](#)

[IMJUDO \(tremelimumab-actl\)](#)

[Imlytic \(Talimogene\)](#)

[INLYTA \(axitinib\)](#)

[Inrebic® \(Fedratinib\)](#)

[Istodax® \(Romidepsin\)](#)

[Jemperli \(Dostarlimab\)](#)

[Kadcyla \(Ado-Trastuzumab Emtansine\)](#)

[Kanjinti \(Trastuzumab-Anns\)](#)

[Kesimpta® \(Ofatumumab\)](#)

[Keytruda® \(Pembrolizumab\) Injection \[Liquid Formulation\] 100 Mg](#)

[Kisqali® Femara® Co-Pack \(Ribociclib And Letrozole\) Tablets](#)

[Kisqali® \(Ribociclib\)](#)

[Kyprolis \(Carilzomib\)](#)

[Levoleucovorin Injection](#)

[LORBRENA \(lorlatinib\)](#)

[Lucentis \(Ranibizumab Injection\)](#)

[Lumakras \(Sotorasib\)](#)

[Lumoxiti \(Moxetumomab Pasudotox-Tdfffk\)](#)

[Lupron Depot \(Leuprolide Acetate For Depot SUSPension\)](#)

[Lupron Depot-Ped \(Leuprolide Acetate For Depot SUSPension\)](#)

[Lutathera® \(Lutetium Lu 177 Dotatate\)](#)

[Lynparza \(Olaparib\)](#)

[Mekinist® \(Trametinib\)](#)

[MEKTOVI \(bibimetinib\)](#)

[Mvasi \(Bevacizumab-Awwb\)](#)

[MYLOTARG \(gemtuzumab\)](#)

[Neulasta \(Pegfilgrastim\)](#)

[Neupogen \(Filgrastim\)](#)

[NIVESTYM \(filgrastim-aafi\)](#)

[Nubeqa \(darolutamide\)](#)

[Nexavar \(sorafenib\)](#)

[NYVEPRIA \(pegfilgrastim-apgf\)](#)

[Ogivri* \(Trastuzumab-Dkst\)](#)

[Onureg® \(Azactidine Tablets\)](#)

[Opdivo® \(Nivolumab\)](#)

[Opdualag™ \(Nivolumab And Relatlimab – Rmbw\)](#)

[Perjeta \(Pertuzumab\)](#)

[Phesgo \(Pertuzumab, Trastuzumab, And Hyaluronidase-Zzxf\)](#)

[Piqray® \(Alpelisib\)](#)

[Pluvicto® \(177Lu-Psma-617\)](#)

[Polivy \(Polatuzumab Vedotin-Piiq\)](#)

[Pomalyst® \(Pomalidomide\)](#)

[Portrazza® \(Necitumumab\) Injection](#)

[Procrit \(Epoetin Alfa\)](#)

[RETACRIT \(epoetin alfa-epbx\)](#)

[Retevmo™ \(Selpercatinib\) Capsules](#)

[Revlimid® \(Lenalidomide\)](#)

[Riabni \(Rituximab-Arrx\)](#)

[Rituxan \(Rituximab\) For Granulomatosis With Polyangiitis \(Gpa\), Microscopic Polyangiitis \(Mpa\) Or](#)

[Pemphigus Vulgaris \(Pv\)](#)

[Rituxan \(Rituximab\) For Oncology](#)

[Rituxan Hycela \(Rituximab/Hyaluronidase Human\)](#)

[Rozlytrek \(Entrectinib\)](#)

[RUXIENCE \(rituximab-pvvr\)](#)

[Rybrevant \(Amivantamab-Vmjjw\)](#)

[Rydapt® \(Midostaurin\)](#)

[Scemblix® \(Asciminib\) Tablets](#)

[Sprycel® \(Dasatinib\)](#)

[Stivarga \(regorafenib\)](#)

[SUTENT \(sunitinib\)](#)

[Synribo \(Omacetaxine\) For Injection](#)

[Tabrecta™ \(Capmatinib\)](#)

[Tafinlar® \(Dabrafenib\)](#)

[Tagrisso \(Osimertinib\)](#)

[TALZENNA \(talazoparib\)](#)

[Tasigna® \(Nilotinib\)](#)

[Tecentriq \(Atezolizumab\)](#)

[TECVAYLI™ \(teclistamab\) Injection, for subcutaneous use](#)

[Thalomid® \(Thalidomide\)](#)

[TORISEL \(temsirolimus\)](#)

[TRAZIMERA \(trastuzumab-qyyp\)](#)

[Treanda \(Bedamustine\) For Injection](#)

[Trisenox \(Arsenice Trioxide\) Injection](#)

[Tykerb® \(Lapatinib\)](#)

[Vectibix \(Panitumumab\)](#)

[Venclexta \(Venetoclax Tablets\)](#)

[Venclexta \(Venetoclax\) Tablets](#)

[Verzenio® \(Abemaciclib\) Tablets](#)

[Vidaza® \(Azacitidine For Injection\)](#)

[Vijoice® \(Alpelisib\)](#)

[VITRAKVI \(Larotrectinib\)](#)

[VIZIMPRO \(dacaomitinib\)](#)

[Votrient® \(Pazopanib\)](#)

[Welireg™ \(Belzutifan\) 40 Mg Tablets](#)

[XALKORI \(crizotinib\)](#)

[Xeloda \(Capecitabine\)](#)

[Xofigo \(radium Ra 223 dichloride\)](#)

[Yervoy® \(Ipilimumab\)](#)

[Yondelis \(Trabectedin\) For Iv Infusion](#)

[Zarxio™ \(Filgrastim-Sndz\)](#)

[Zelboraf \(Vemurafenib\)](#)

[Ziextenso® \(Pegfilgrastim-Bmez\)](#)

[ZIRABEV \(bevacizumab-bvzr\)](#)

[Zolinza® \(Vorinostat\) 100 Mg Capsules](#)

[Zykadia® \(Ceritinib\)](#)

[Zynlonta \(loncastuximab tesirine\)](#)

[Zytiga \(Abiraterone\) Tablets](#)

Additional resources

NeedyMeds

- [Phone application for iPhone & Android for NeedyMeds Drug Discount Cards](#)
- Any medication not included in current document that has a patient assistance program will likely be located on the NeedyMeds website

Wellvista (10-14 days for application processing)

Eligibility

1. South Carolina Resident, which requires proof as follows:
 - a. Copy of Driver's license, State ID card, utility bill, or ANY bill with **YOUR** name and current address on it (PO box not valid)
2. Copy of Photo ID
 - a. Driver's license
 - b. State ID card
 - c. Passport
3. Uninsured
4. At or below 250% FPL

| Household size | Annual household income (\$) threshold (<250% FPL) |
|----------------|---|
| 1 | 33,975 |
| 2 | 45,775 |
| 3 | 57,575 |
| 4 | 69,375 |
| 5 | 81,175 |

[Click for FPL for household larger than 5](#)

- a. Must provide proof of income for **ALL** individuals in house
 - i. Acceptable income documents:
 1. Two current, consecutive paystubs
 - a. No older than 45 days
 2. Pension/retirement
 3. Social security
 4. SS disability with Notice of Award
 5. Child support
 6. Alimony
 7. Unemployment
 8. Worker's compensation
 9. Renal income
5. Provider should e-scribe medications to Welvista
 - a. If hardcopy prescriptions are provided, they will need mailed to Welvista
 - i. Welvista 121 Greystone Blvd, Columbia, SC, 29210
6. Applications should be mailed, faxed, or emailed

- a. Mail: Welvista 121 Greystone Blvd, Columbia, SC, 29210
 - b. Fax: (803)-933-0489
 - c. Email: applications@welvista.org
7. Prescription refill calls should be made 10 days before refill is needed
- a. If phone call is not answered, leave message with name, date of birth, and phone number
 - i. Call will be returned within 24-48 hours (do NOT leave multiple messages)

[List of medications](#) for Welvista

Contact info-Phone: (803)-933-9184 Fax: (803)-933-0489


RxOutreach

Eligibility

1. US resident
2. Below 400% FPL; does NOT require proof of income
 - a. Regardless of insurance status (uninsured or insured)

| Household size | Annual household income (\$) threshold (<400% FPL) |
|----------------|---|
| 1 | 54,360 |
| 2 | 73,240 |
| 3 | 92,120 |
| 4 | 111,000 |
| 5 | 129,880 |
| ≥5 | Add 4,720 for each additional person |

- [List of medications by disease state](#)
- [List of medications complete with pricing](#)
- Medications are sent to patient's home directly through mail order



Contact info-Phone: 1-888-796-1234 Fax: 1-800-875-6591

[Walmart \\$4.00 prescription list](#)

[Pan Foundation and HealthWell Foundation](#)

- Provides 12 month grants to assist with co-pays, health insurance premiums, out-of-pocket medication costs, transportation costs associated with medical care

- Disease state based and grants/open spots become closed on the website

Following disease states included:

- Acromegaly
- Acute Myeloid Leukemia
- Amyloidosis
- Ankylosing Spondylitis
- Asthma
- Atopic Dermatitis
- Basal Cell Carcinoma
- Biliary Tract Cancer
- Bipolar Disorder
- Bladder Cancer
- Chronic Lymphocytic Leukemia
- Colorectal Cancer
- COVID-19 Financial Support
- Cushing's Disease or Syndrome
- Diabetic Foot Ulcers
- Fabry Disease
- Fabry Disease Premium
- Gaucher Disease
- Glioblastoma Multiforme
- Graft Vs Host Disease
- Heart Failure
- Hemolytic Uremic Syndrome
- Hemophilia
- Hemophilia Premium
- Hepatitis C
- HIV Treatment and Prevention
- Hypercholesterolemia
- Hyperkalemia
- Immune Thrombocytopenic Purpura
- Inflammatory Bowel Disease
- Inherited Retinal Disease
- Inherited Retinal Disease Premium
- Liver Cancer
- Macular Diseases
- Mantle Cell Lymphoma
- Melanoma
- Metastatic Breast Cancer
- Multiple Myeloma
- Multiple Sclerosis
- Myasthenia Gravis
- Neuromyelitis Optica Spectrum Disorder
- Neurotrophic Keratitis
- Neutropenia
- Non-Hodgkin's Lymphoma
- Non-Small Cell Lung Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Parkinson's Disease
- Paroxysmal Nocturnal Hemoglobinuria
- Philadelphia Chromosome Negative Myeloproliferative Neoplasms
- Plaque Psoriasis
- Postmenopausal Osteoporosis
- Prostate Cancer
- Psoriatic Arthritis
- Pulmonary Hypertension
- Renal Cell Carcinoma
- Retinal Vein Occlusion
- Rheumatoid Arthritis
- Schizophrenia
- Short Bowel Syndrome
- Short Bowel Syndrome Premium
- Sickle Cell Disease
- Small Cell Lung Cancer
- Spinal Muscular Atrophy
- Transportation
- Type 2 Diabetes
- Uveitis
- Venous Leg Ulcers
- Von Willebrand Disease
- Waldenstrom Macroglobulinemia

Re-enrollment information per PAP program

AbbVie

- Submit same application and process
- Company does send application in mail for Medicare patients

Amgen

- Company will send application for patients already enrolled

AstraZeneca

- Automatically re-enrolling Medicare patients for 2023.
- Each patient will need new prescription e-scribed

Bausch Health

- The program requires that you re-enroll every year by completing a Bausch Health Patient Assistance Program application form. A notice regarding re-enrollment will be sent to you 60 days prior to the anniversary date of your participation in the program or, in some cases, by December 31.

Boehringer Ingelheim

- Re-enrollment forms are sent out after October 15th to the patient's home

Bristol Myers Squibb

- Beginning in November, a new application will be mailed to the patient and the provider office will be faxed that it is time to re-enroll patient
- Re-enrollment application is the same as initial application

end on 12/31/2022. Attached to this fax is a renewal application. We have also mailed a copy of the application to your patient.

If your patient would like to reapply for assistance from the BMSPAF:

- Please ensure the application is completed, signed, and dated, and that all requested documentation is included, such as proof of income and, for Medicare enrollees, out-of-pocket prescription expenses.
- Incomplete applications will result in processing delays.
- No later than 30 days from the date of this letter, please return completed and signed applications to BMSPAF:
 - By fax: (800) 736-1611
 - By U.S. Mail: BMSPAF, PO BOX 220769, Charlotte, NC 28222-0769

The submission of the application and documentation is not a guarantee that we will continue to provide medicine to your patient. Our program rules are subject to change without notice at any time.

If your patient is enrolled in a Medicare Plan:

- They may not be eligible for the BMSPAF in 2023 until they have spent 3% of their annual household income on prescription medications (for the entire household) in 2023.

How we prioritize our review of applications at the beginning of the year (January—March):

- Applications will be prioritized for review based on the patient's projected date of service/refill due date.
- For the rest of the year, we will prioritize by the date complete applications are received.

Please note that BMSPAF is not responsible for providing medication for missed dates of service and/or missed refills due to late submissions or incomplete applications.

- Medicare part D patients **will need to spend 3%** out of pocket on prescriptions each calendar year

GlaxoSmithKline (GSK)

- Company will send out re-enrollment forms to patient's home 2 months prior to enrollment period end date
- Patients with Medicare Part D need to re-apply to the GSK Patient Assistance Program each calendar year after they have spent at least \$600 on prescription medicines through their Medicare Part D Prescription Drug Plan.
 - Fax or mail your completed enrollment form and documents to the GSK Patient Assistance Program. Faxed prescriptions are only valid if faxed directly from a physician's office. Applicant's name and date of birth must be on each faxed page.
 - If you are eligible for continued assistance through the GSK Patient Assistance Program, your first refill will automatically be sent to the address provided on the application.

Janssen

- All patients up for renewal will receive an application approximately one month prior to enrollment end date, which include pre-filled patient and provider information
 - Renewal application is otherwise identical to initial application
- Medicare part D patients **will need to spend 4%** out of pocket on prescriptions each calendar year

Lilly

- Letter will be sent to patient only notifying them that it is time to renew 2.5-3 months before enrollment end date
- Application is the same as initial enrollment application
- Medicare patients can start re-enrollment November 2nd for the following calendar year

Merck

- Every patient must submit renewal application, which is same as original application
- Renewal application for Medicare patients sent out by company if requested and has two questions in addition to a new application
 - Signature for financial hardship
 - Yes or no for Medicare B or D
- Cannot be submitted until December

MyPraluent

- Re-enrollment process is completion of a new original application
 - Company does **NOT** send a renewal application to patients

- Approval through December 31st for Medicare beneficiaries, 365 days for uninsured patients

Mylan (Viatri)

- Renewal application is the same as original application
- Can submit renewal application 4-6 weeks prior to enrollment end date, which is 365 days from date approved

Nestle Health

- Will need to reapply about 30 days from your application expiration date; company will send a reminder letter in the mail when it is time to reapply
- Medicare patients will need to reapply after open enrollment annually

Novartis

- Patient will receive re-enrollment application 45 days prior to enrollment end date
- Providers office will be faxed same day re-enrollment application is sent in the mail
- Re-enrollment application is the same as the original application

Our records indicate that your patient(s) listed on the following page are enrolled in the NPAF and their enrollment will expire on December 31st.

Please note the following:

| Who | Actions Needed | Received by NPAF before | |
|------------|--|-------------------------|------------------------|
| Prescriber | Complete and sign your portion of the NPAF application | December 15 | Fax: 1-855-817-2711 |
| | Include a separate 12-month prescription with 90-day supply when you fax your portion of the NPAF application If your patient(s) has insurance and their policy requires a Prior Authorization (PA), you will need to attach the PA Appeal Denial with your portion of the application. | | |
| Patient | Your patient needs to complete their portion of the NPAF application including providing proof of income and copies of insurance cards | December 15 | |

Go to www.PAP.Novartis.com. To download an PDF of the English or Spanish application.

If you or your staff have any questions, please call NPAF's dedicated healthcare provider line at 1-800-277-2254 option 2, Monday through Friday, 8:00 am to 8:00 pm ET.

Sincerely,
Novartis Patient Assistance Foundation, Inc.

Attached Documents: NPAF Application

Novo Nordisk

- Re-enrollment can begin 30 days prior to the end of enrollment end date or after October 15th for Medicare patients
 - Medicare part D patients are approved for calendar year, uninsured or Medicare part A/B are approved for 365 days
- Re-enrollment application is identical to original application
- Company typically sends application for renewal by mail to patient's house

Otsuka

- Patients need to reapply 30-45 days prior to enrollment end date
 - Medicare patients: December 31st
 - Uninsured patients: 365 days
- Company will reach out to patient via telephone to discuss re-enrollment each year

Pfizer

- Medicare patients can begin reapplying in October for the subsequent calendar year
- Company does **NOT** send renewal reminder or application
- Re-enrollment application is the same as the original

Sanofi

- Medicare patients **CANNOT** reapply until January of the calendar year they are applying for

- Uninsured patients can apply for re-enrollment 60 days prior to enrollment end date
 - Uninsured patients enrollment end date is 365 days, Medicare through end of the calendar year
- Company does **NOT** send out renewal reminders or re-enrollment forms

TAKEDA

- Company sends letter 60 days prior to enrollment end date as reminder to re-enroll
 - Medicare patients enrollment end date is December 31st annually
 - Uninsured patients enrollment end date 365 days from approval date
- Company does **NOT** send application to patient
- Re-enrollment application same as original application

TEVA

- Re-enrollment can begin 30 days prior to enrollment end date
 - Enrollment end date is 365 days from approval date
 - Only accepts Medicare A,B or uninsured
- Application and fax are sent to provider office prior to enrollment end date
- Letter is sent to patient prior to enrollment date

Requesting a refills per Patient Assistance Program (PAP)

AbbVie

1. Press number for your desired medication
2. Press 1 for patient
3. Press 1 to order a refill
 - Press 1 again for refill
 1. Enter DOB (dd/mm/yyyy)
 - Press 1 to confirm entry
 2. Enter 5 digit zip code
 - Press 1 to confirm entry
 3. Press number corresponding to desired medication needing refilled
 - Press 1 if address has not changed where medication needs shipped

BAUSCH HEALTH

1. Press 1 for patient
2. Press 4 for refill
3. Enter DOB as MM/DD/YYYY
 - Press 1 to confirm DOB

4. Enter last 4 digits of social security number
-Press 1 to confirm social security number
5. Press 1 for enter prescription number
6. Enter prescription number
-Press 1 to confirm prescription number

Boehringer Ingelheim

1. Press 2
2. Enter prescription number followed by the # key
3. Press 1 to confirm prescription number

GSK

1. Press 1 for refill
2. Enter 10 digit phone number (###-###-####)
3. Enter 7 digit prescription number on medication vial
 - Found in yellow rectangle above name on prescription label
 1. If prescription number cannot be found or is not available, patient will be transferred to representative to request refill

Novartis

1. Press 1
2. Press 1 to start new refill request
3. Enter 10 digit prescription number
 - If prescription number not available press 1
 1. Enter 10 digit phone number (###-###-####) associated with account
 - If additional help is needed, press 1 to speak with representative

Pfizer

1. Say name of medication calling about
2. Say patient
3. Say no for calling about enrollment status
4. Patient will be connected to representative to request refill

Produced by:

Kyle Ames, PharmD, BCPS
Clinical Pharmacy Specialist – Transitions of Care
Last revised:01/30/2023
Copyright 6/3/2022